CDC7 Inhibitor Combinational Therapy
20250090495 ยท 2025-03-20
Inventors
- Tom LIN (Sydney, AU)
- Irene WANG (Taipei, TW)
- Mark G. Frattini (Rigewood, NJ, US)
- Hakim Djaballah (Scarsdale, NY, US)
- Thomas J. Kelly (New York, NY, US)
Cpc classification
A61K9/0019
HUMAN NECESSITIES
C12Q2600/106
CHEMISTRY; METALLURGY
A61K31/352
HUMAN NECESSITIES
A61N5/10
HUMAN NECESSITIES
C09B13/02
CHEMISTRY; METALLURGY
A61K31/122
HUMAN NECESSITIES
C09B61/00
CHEMISTRY; METALLURGY
International classification
A61K31/122
HUMAN NECESSITIES
C09B13/02
CHEMISTRY; METALLURGY
C09B61/00
CHEMISTRY; METALLURGY
A61K31/352
HUMAN NECESSITIES
A61N5/10
HUMAN NECESSITIES
Abstract
The present invention provides a method of treatment and composition for CDC7 inhibitor combinational therapy for treatment of proliferative diseases. In an embodiment, the composition of the present invention comprises a therapeutically effective amount of a combination of a CDC7 inhibitor of the present invention or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents. In an embodiment, the CFC7 inhibitor comprises granaticin B. In an embodiment, the antneoplastic agent comprises azacitidine and venetoclax. The present invention further provides a method of treatment comprising the step of administration to a subject suffering from proliferative disease of any embodiment of the composition of the present invention.
Claims
1. A method of treatment of a proliferative disorder of a subject comprising step of administration of a pharmaceutical composition comprising a therapeutically effective amount of a combination of (a) a compound of Formula (A) or (B) or a pharmaceutically acceptable salt thereof and (b) one or more antineoplastic agents to the subject wherein: A compound of Formula (A) or (B): ##STR00043## each instance of R.sup.1 and R.sup.4 is independently selected from the group consisting of hydrogen, carbonyl, silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; each instance of R.sup.2 and R.sup.3 is independently selected from the group consisting of hydrogen, halogen, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, carbonyl, silyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R.sup.2 and R.sup.3 are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group; R.sup.5 is hydrogen and R.sup.6 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; or R.sup.5 and R.sup.6 are joined to form a direct bond; R.sup.7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R.sup.12 is hydrogen, carbonyl, silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; and each instance of R.sup.13 and R.sup.14 is independently selected from the group consisting of hydrogen, halogen, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, carbonyl, silyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R.sup.13 and R.sup.14 are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group.
2. The method of claim 1, wherein the compound of formula A or B comprises granaticin B wherein the granticin B comprises amorphous form of the granticin B or any crystalline form of the granaticin B.
3. The method of claim 2, wherein the compound of formula A or B comprises crystalline form A of granaticin B.
4. The method of claim 1, wherein the one or more antineoplastic agents comprise hydroxyurea, granulocyte colony stimulating factor (G-CSF), BCL2 inhibitor, hypomethylating agent, chemotherapeutic agent or a combination thereof.
5. The method of claim 4, wherein the BCL2 inhibitor comprises venetoclax
6. The method of claim 4, wherein the hypomethylating agent comprises azacitidine, decitabine or a combination thereof.
7. The method of claim 4, wherein the chemotherapeutic agent comprises cytarabine, daunorbicin, idarubicin, anthracycline, cladribine or a combination thereof.
8. The method of claim 1, wherein the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agents comprises azacitidine and venetoclax.
9. The method of claim 1, wherein the one or more antineoplastic agent comprises fludarabine, arabinofuranosyl cytidine, granulocyte colony-stimulating factor and idarubicin (FLAG-IDA).
10. The method of claim 9, wherein administration step comprises administration of the standard FLAG-IDA chemotherapy regimen administered in combination with the compound of Formula (A) or (B).
11. The method of claim 9, wherein administration step comprises administration of the standard FLAG-IDA chemotherapy regimen administered in combination with the compound of Formula (A) or (B) and venetoclax.
12. The method of claim 1, wherein the one or more antineoplastic agent comprises cytarabine and anthracycline antibiotic and wherein administration step comprises the standard 7 days of standard-dose cytarabine followed by 3 days of anthracycline antibiotic chemotherapy regimen administered in combination with the compound of Formula (A) or (B).
13. The method of claim 4, wherein the chemotherapeutic agent comprises anti-estrogens such as tamoxifen, raloxifene, and megestrol, LHRH agonists such as goscrclin and leuprolide, anti-androgens such as flutamide and bicalutamide, photodynamic therapies such as vertoporfin (BPD-MA), phthalocyanine, photosensitizer Pc4, and demethoxy-hypocrellin A (2BA-2-DMHA, nitrogen mustards such as cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, estramustine, and melphalan, nitrosoureas such as carmustine (BCNU) and lomustine (CCNU), alkylsulphonates such as busulfan and treosulfan, triazenes such as dacarbazine, temozolomide, platinum containing compounds such as cisplatin, carboplatin, oxaliplatin, vinca alkaloids such as vincristine, vinblastine, vindesine, and vinorelbine, taxoids such as paclitaxel or a paclitaxel equivalent such as nanoparticle albumin-bound paclitaxel (ABRAXANE), docosahexaenoic acid bound-paclitaxel (DHA-paclitaxel), Taxoprexin, polyglutamate bound-paclitaxel (PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX), the tumor-activated prodrug (TAP) ANG1005 (Angiopep-2 bound to three molecules of paclitaxel), paclitaxel-EC-1 (paclitaxel bound to the erbB2-recognizing peptide EC-1), and glucose-conjugated paclitaxel, 2-paclitaxel methyl 2-glucopyranosyl succinate; docetaxel, taxol, epipodophyllins such as etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mytomycin C, anti-metabolites, DHFR inhibitors such as methotrexate, dichloromethotrexate, trimetrexate, edatrexate, IMP dehydrogenase inhibitors such as mycophenolic acid, tiazofurin, ribavirin, and EICAR, ribonuclotide reductase inhibitors such as hydroxyurea and deferoxamine, uracil analogs such as 5-fluorouracil (5-FU), floxuridine, doxifluridine, ratitrexed, tegafur-uracil, capecitabine, cytosine analogs such as cytarabine (ara C), cytosine arabinoside, and fludarabine, purine analogs such as mercaptopurine and Thioguanine, Vitamin D3 analogs such as EB 1089, CB 1093, and KH 1060, isoprenylation inhibitors such as lovastatin, dopaminergic neurotoxins such as 1-methyl-4-phenylpyridinium ion, cell cycle inhibitors such as staurosporine, actinomycin such as actinomycin D, dactinomycin, bleomycin such as bleomycin A2, bleomycin B2, peplomycin, anthracycline such as daunorubicin, doxorubicin, pegylated liposomal doxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin, mitoxantrone, MDR inhibitors such as verapamil, Ca.sup.2+ ATPase inhibitors such as thapsigargin, imatinib, thalidomide, lenalidomide, tyrosine kinase inhibitors such as axitinib (AG013736), bosutinib (SKI-606), cediranib (RECENTIN, AZD2171), dasatinib (SPRYCEL, BMS-354825), erlotinib (TARCEVA), gefitinib (IRESSA), imatinib (Gleevec, CGP57148B, STI-571), lapatinib (TYKERB, TYVERB), lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib (TASIGNA), semaxanib (semaxinib, SU5416), sunitinib (SUTENT, SU11248), toceranib (PALLADIA), vandetanib (ZACTIMA, ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab (HERCEPTIN), bevacizumab (AVASTIN), rituximab (RITUXAN), cetuximab (ERBITUX), panitumumab (VECTIBIX), ranibizumab (Lucentis), nilotinib (TASIGNA), sorafenib (NEXAVAR), everolimus (AFINITOR), alemtuzumab (CAMPATH), gemtuzumab ozogamicin (MYLOTARG), temsirolimus (TORISEL), ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120 (VARGATEF), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, and/or XL228, proteasome inhibitors such as bortezomib (VELCADE), mTOR inhibitors such as rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe) and OSI-027 (OSI), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbizine, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurosidine, leurosine, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin, aminopterin, and hexamethyl melamine, Gemtuzumab, ozogamicin, Idarubicin, CPX-351, Enasidenib (IDH2 inibitor), FTL3 inhibitors such as Sunitinib, Midostaurin, Lestaurtinib, Crenolanib, Gilteritinib, Sorafenib, Ponatinib, Quizartinib) Ivosidenib (IDH1 inhibitor), Venetoclax (BCL-2 inhibitor) and Glasdegib, rituximab, ofatuzumab (Anti-CD20), inotuzumab ozogamicin (Anti-CD22), blinatumomab (Anti-CD19), and Tisagenlecleucel, tyrosine kinase inhibitor (Imatinib, Dasatinib, Nilotinib, Ponatinib, Bosatinib, Asciminib) with/without chemotherapy (Clofarabine, Nelarabine, Liposomal vincristine, MOpAD, Hyper-CVAD, BFM, etc) or steroid, inotuzumab ozogamicin, blinatumomab, Tisagenlecleucel, or a combination thereof.
14. The method of claim 1, wherein the proliferative disorder comprises cancer.
15. The method of claim 1, wherein the proliferation disorder comprises blood cancers wherein the blood cancers comprise acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and/or chronic lymphoblastic leukemia (CLL).
16. The method of claim 14, wherein the cancer comprises a mutation.
17. The method of claim 16, wherein the genetic mutation comprises a RAS mutation, an EGFR mutation, a KRAS mutation, a p53 mutation, a BRAF mutation, a EVI1 mutation, a Flt-3 mutation, WT-1 mutation, a cyclin D mutation, a PTEN mutation, an ALB kinase mutation, a chromosomal abnormality or a combination thereof.
18. The method of claim 14, wherein the cancer is a multi-drug resistant (MDR) cancer.
19. The method of claim 14, wherein the cancer is relapsed and/or refractory cancer.
20. The method of claim 1 further comprising the step of administration of radiation.
21. The method of claim 1 wherein the ratio by weight of the compound of Formula (A) or (B) to the antineoplastic agent is about 500:0.1 to about 0.1:500.
22. The method of claim 1, wherein the compound of Formula (A) or (B) is of the Formula (A-3): ##STR00044## or a pharmaceutically acceptable salt thereof.
23. The method of claim 1, wherein the compound of Formula (A) or (B) is of the Formula (A-7): ##STR00045## or a pharmaceutically acceptable salt thereof, wherein each instance of R.sup.9 and R.sup.10 is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, carbonyl, silyl, sulfonyl, and sulfinyl.
24. The method of claim 1, wherein the compound of Formula (A) or (B) is of the Formula (B-1): ##STR00046## or a pharmaceutically acceptable salt thereof.
25. The method of claim 1, wherein the compound of Formula (A) or (B) is selected from the group consisting of: ##STR00047## ##STR00048## and pharmaceutically acceptable salts thereof.
26. The method of claim 1, wherein the therapeutically effective amount of the pharmaceutical composition is administered to the subject by intravenous injection, intraarterial injection, intraperitoneal injection, intrapleural injection, intracardiac injection, or intrapericardial injection.
27. The method of claim 1, wherein the compound of Formula (A) or (B) is administered to a subject simultaneously with the antineoplastic agent.
28. The method of claim 1, wherein the compound of Formula (A) or (B) is administered to a subject separately sequentially before the administration of antineoplastic agent with time interval in between the two administrations of about 0.5 hour, about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 20 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 2 weeks, about 3 weeks or about 4 weeks, about 6 weeks or about 8 weeks.
29. The method of claim 1, wherein the compound of Formula (A) or (B) is administered to a subject after the administration of antineoplastic agent with time interval in between the two administrations of about 1 hour, about 2 hours, about 5 hours, about 10 hours, about 20 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks or about 8 weeks.
30. A pharmaceutical composition comprising a combination of (a) a compound of Formula (A) or (B) and (b) one or more antineoplastic agents, wherein the compound of Formula (A) or (B) and the one or more antineoplastic agents are present in each case in free form, in the form of a pharmaceutically acceptable salt, or hydrate thereof, and wherein A compound of Formula (A) or (B): ##STR00049## each instance of R.sup.1 and R.sup.4 is independently selected from the group consisting of hydrogen, carbonyl, silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; each instance of R.sup.2 and R.sup.3 is independently selected from the group consisting of hydrogen, halogen, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, carbonyl, silyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R.sup.2 and R.sup.3 are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group; R.sup.5 is hydrogen and R.sup.6 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; or R.sup.5 and R.sup.6 are joined to form a direct bond; R.sup.7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; R.sup.12 is hydrogen, carbonyl, silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; and each instance of R.sup.13 and R.sup.14 is independently selected from the group consisting of hydrogen, halogen, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, carbonyl, silyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R.sup.13 and R.sup.14 are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group.
31. The pharmaceutical composition of claim 30, wherein the compound of formula A or B comprises granaticin B wherein the ganaticin B comprises amourphous form of the granaticin B or any crystalline form of the granaticin B.
32. The pharmaceutical composition of claim 31, wherein the compound of formula A or B comprises crystalline form A of granaticin B.
33. The pharmaceutical composition of claim 30, wherein the one or more antineoplastic agents comprise hydroxyurea, granulocyte colony stimulating factor (G-CSF), BCL2 inhibitor, hypomethylating agent, chemotherapeutic agent or a combination thereof.
34. The pharmaceutical composition of claim 33, wherein the BCL2 inhibitor comprises venetoclax
35. The pharmaceutical composition of claim 33, wherein the hypomethylating agent comprises azacitidine, decitabine or a combination thereof.
36. The pharmaceutical composition of claim 33, wherein the chemotherapeutic agent comprises cytarabine, daunorbicin, idarubicin, anthracycline, cladribine or a combination thereof.
37. The pharmaceutical composition of claim 30, wherein the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agents comprises azacitidine and venetoclax.
38. The pharmaceutical composition of claim 30, wherein the one or more antineoplastic agent comprises fludarabine, arabinofuranosyl cytidine, granulocyte colony-stimulating factor and idarubicin (FLAG-IDA).
39. The pharmaceutical composition of claim 33, wherein the chemotherapeutic agent comprises anti-estrogens such as tamoxifen, raloxifene, and megestrol, LHRH agonists such as goscrclin and leuprolide, anti-androgens such as flutamide and bicalutamide, photodynamic therapies such as vertoporfin (BPD-MA), phthalocyanine, photosensitizer Pc4, and demethoxy-hypocrellin A (2BA-2-DMHA, nitrogen mustards such as cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, estramustine, and melphalan, nitrosoureas such as carmustine (BCNU) and lomustine (CCNU), alkylsulphonates such as busulfan and treosulfan, triazenes such as dacarbazine, temozolomide, platinum containing compounds such as cisplatin, carboplatin, oxaliplatin, vinca alkaloids such as vincristine, vinblastine, vindesine, and vinorelbine, taxoids such as paclitaxel or a paclitaxel equivalent such as nanoparticle albumin-bound paclitaxel (ABRAXANE), docosahexaenoic acid bound-paclitaxel (DHA-paclitaxel), Taxoprexin, polyglutamate bound-paclitaxel (PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX), the tumor-activated prodrug (TAP) ANG1005 (Angiopep-2 bound to three molecules of paclitaxel), paclitaxel-EC-1 (paclitaxel bound to the erbB2-recognizing peptide EC-1), and glucose-conjugated paclitaxel, 2-paclitaxel methyl 2-glucopyranosyl succinate; docetaxel, taxol, epipodophyllins such as etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mytomycin C, anti-metabolites, DHFR inhibitors such as methotrexate, dichloromethotrexate, trimetrexate, edatrexate, IMP dehydrogenase inhibitors such as mycophenolic acid, tiazofurin, ribavirin, and EICAR, ribonuclotide reductase inhibitors such as hydroxyurea and deferoxamine, uracil analogs such as 5-fluorouracil (5-FU), floxuridine, doxifluridine, ratitrexed, tegafur-uracil, capecitabine, cytosine analogs such as cytarabine (ara C), cytosine arabinoside, and fludarabine, purine analogs such as mercaptopurine and Thioguanine, Vitamin D3 analogs such as EB 1089, CB 1093, and KH 1060, isoprenylation inhibitors such as lovastatin, dopaminergic neurotoxins such as 1-methyl-4-phenylpyridinium ion, cell cycle inhibitors such as staurosporine, actinomycin such as actinomycin D, dactinomycin, bleomycin such as bleomycin A2, bleomycin B2, peplomycin, anthracycline such as daunorubicin, doxorubicin, pegylated liposomal doxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin, mitoxantrone, MDR inhibitors such as verapamil, Ca.sup.2+ ATPase inhibitors such as thapsigargin, imatinib, thalidomide, lenalidomide, tyrosine kinase inhibitors such as axitinib (AG013736), bosutinib (SKI-606), cediranib (RECENTIN, AZD2171), dasatinib (SPRYCEL, BMS-354825), erlotinib (TARCEVA), gefitinib (IRESSA), imatinib (Gleevec, CGP57148B, STI-571), lapatinib (TYKERB, TYVERB), lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib (TASIGNA), semaxanib (semaxinib, SU5416), sunitinib (SUTENT, SU11248), toceranib (PALLADIA), vandetanib (ZACTIMA, ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab (HERCEPTIN), bevacizumab (AVASTIN), rituximab (RITUXAN), cetuximab (ERBITUX), panitumumab (VECTIBIX), ranibizumab (Lucentis), nilotinib (TASIGNA), sorafenib (NEXAVAR), everolimus (AFINITOR), alemtuzumab (CAMPATH), gemtuzumab ozogamicin (MYLOTARG), temsirolimus (TORISEL), ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120 (VARGATEF), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, and/or XL228, proteasome inhibitors such as bortezomib (VELCADE), mTOR inhibitors such as rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe) and OSI-027 (OSI), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbizine, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurosidine, leurosine, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin, aminopterin, and hexamethyl melamine, Gemtuzumab, ozogamicin, Idarubicin, CPX-351, Enasidenib (IDH2 inibitor), FTL3 inhibitors such as Sunitinib, Midostaurin, Lestaurtinib, Crenolanib, Gilteritinib, Sorafenib, Ponatinib, Quizartinib) Ivosidenib (IDH1 inhibitor), Venetoclax (BCL-2 inhibitor) and Glasdegib, rituximab, ofatuzumab (Anti-CD20), inotuzumab ozogamicin (Anti-CD22), blinatumomab (Anti-CD19), and Tisagenlecleucel, tyrosine kinase inhibitor (Imatinib, Dasatinib, Nilotinib, Ponatinib, Bosatinib, Asciminib) with/without chemotherapy (Clofarabine, Nelarabine, Liposomal vincristine, MOpAD, Hyper-CVAD, BFM, etc) or steroid, inotuzumab ozogamicin, blinatumomab, Tisagenlecleucel, or a combination thereof.
40. The pharmaceutical composition of claim 30 wherein the ratio by weight of the compound of Formula (A) or (B) to the antineoplastic agent is about 500:0.1 to about 0.1:500.
41. The pharmaceutical composition of claim 30, wherein the compound of Formula (A) or (B) is of the Formula (A-3): ##STR00050## or a pharmaceutically acceptable salt thereof.
42. The pharmaceutical composition of claim 30, wherein the compound of Formula (A) or (B) is of the Formula (A-7): ##STR00051## or a pharmaceutically acceptable salt thereof, wherein each instance of R.sup.9 and R.sup.10 is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, carbonyl, silyl, sulfonyl, and sulfinyl.
43. The pharmaceutical composition of claim 30, wherein the compound of Formula (A) or (B) is of the Formula (B-1): ##STR00052## or a pharmaceutically acceptable salt thereof.
44. The pharmaceutical composition of claim 30, wherein the compound of Formula (A) or (B) is selected from the group consisting of: ##STR00053## ##STR00054## and pharmaceutically acceptable salts thereof.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0015]
[0016]
[0017]
[0018] FIG. 4. Granaticin A induces Caspase 3-mediated apoptosis: 10 hours following release of G1 synchronized PhALL3.1 cells into either control (DMSO) or granaticin A, cell samples were taken and caspase 3 activity was measured using a standard fluorometric assay as described in Gao et al., Dimeric Smac/Diablo Peptide Directly Relieves Caspase-3 Inhibition by XIAP Journal Biological Chemistry (2007) 282:30718-30727.
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
DEFINITIONS
[0039] The compositions of the present invention can comprise, consist of, or consist essentially of the essential elements and limitations of the invention described herein, as well as any of the additional or optional ingredients, components, or limitations described herein.
[0040] As used in the specification and claims, the singular form a an and the include plural references unless the context clearly dictates otherwise. For example, the term a cell includes a plurality of cells, including mixtures thereof.
[0041] About in the context of amount values refers to an average deviation of maximum 20%, preferably 10% or more preferably 5% based on the indicated value. For example, an amount of about 30 mol % anionic lipid refers to 30 mol % 6 mol %, preferably 30 mol % 3 mol % or more preferably 30 mol % 1.5 mol % anionic lipid with respect to the total lipid/amphiphile molarity.
[0042] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75.sup.th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March's Advanced Organic Chemistry, 5.sup.th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3.sup.rd Edition, Cambridge University Press, Cambridge, 1987.
[0043] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind. 1972). The invention additionally encompasses compounds as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.
[0044] When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example C.sub.1-6 alkyl is intended to encompass, C.sub.1, C.sub.2, C.sub.3, C.sub.4, C.sub.5, C.sub.6, C.sub.1-6, C.sub.1-5, C.sub.1-4, C.sub.1-3, C.sub.1-2, C.sub.2-6, C.sub.2-5, C.sub.2-4, C.sub.2-3, C.sub.3-6, C.sub.3-5, C.sub.3-4, C.sub.4-6, C.sub.4-5, and C.sub.5-6 alkyl. As used herein, alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 10 carbon atoms (C.sub.1-10 alkyl). In some embodiments, an alkyl group has 1 to 9 carbon atoms (C.sub.1-9 alkyl). In some embodiments, an alkyl group has 1 to 8 carbon atoms (C.sub.1-8 alkyl). In some embodiments, an alkyl group has 1 to 7 carbon atoms (C.sub.1-7 alkyl). In some embodiments, an alkyl group has 1 to 6 carbon atoms (C.sub.1-6 alkyl). In some embodiments, an alkyl group has 1 to 5 carbon atoms (C.sub.1-5 alkyl). In some embodiments, an alkyl group has 1 to 4 carbon atoms (C.sub.1-4 alkyl). In some embodiments, an alkyl group has 1 to 3 carbon atoms (C.sub.1-3 alkyl). In some embodiments, an alkyl group has 1 to 2 carbon atoms (C.sub.1-2 alkyl). In some embodiments, an alkyl group has 1 carbon atom (C.sub.1 alkyl). In some embodiments, an alkyl group has 2 to 6 carbon atoms (C.sub.2-6 alkyl). Examples of C.sub.1-6 alkyl groups include methyl (C.sub.1), ethyl (C.sub.2), n-propyl (C.sub.3), isopropyl (C.sub.3), n-butyl (C.sub.4), tert-butyl (C.sub.4), sec-butyl (C.sub.4), iso-butyl (C.sub.4), n-pentyl (C.sub.5), 3-pentanyl (C.sub.5), amyl (C.sub.5), neopentyl (C.sub.5), 3-methyl-2-butanyl (C.sub.5), tertiary amyl (C.sub.5), and n-hexyl (C.sub.6). Additional examples of alkyl groups include n-heptyl (C.sub.7), n-octyl (C.sub.8) and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an unsubstituted alkyl) or substituted (a substituted alkyl) with one or more substituents. In certain embodiments, the alkyl group is an unsubstituted C.sub.1-10 alkyl (e.g., CH.sub.3). In certain embodiments, the alkyl group is a substituted C.sub.1-10 alkyl.
[0045] Perhaloalkyl is a substituted alkyl group as defined herein wherein all of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo. In some embodiments, the alkyl moiety has 1 to 8 carbon atoms (C.sub.1-8 perhaloalkyl). In some embodiments, the alkyl moiety has 1 to 6 carbon atoms (C.sub.1-6 perhaloalkyl). In some embodiments, the alkyl moiety has 1 to 4 carbon atoms (C.sub.1-4 perhaloalkyl). In some embodiments, the alkyl moiety has 1 to 3 carbon atoms (C.sub.1-3 perhaloalkyl). In some embodiments, the alkyl moiety has 1 to 2 carbon atoms (C.sub.1-2 perhaloalkyl). In some embodiments, all of the hydrogen atoms are replaced with fluoro. In some embodiments, all of the hydrogen atoms are replaced with chloro. Examples of perhaloalkyl groups include CF.sub.3, CF.sub.2CF.sub.3, CF.sub.2CF.sub.2CF.sub.3, CCl.sub.3, CFCl.sub.2, CF.sub.2Cl, and the like.
[0046] As used herein, alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon double bonds (C.sub.2-10 alkenyl). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (C.sub.2-9 alkenyl). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (C.sub.2-8 alkenyl). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (C.sub.2-7 alkenyl). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (C.sub.2-6 alkenyl). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (C.sub.2-5 alkenyl). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (C.sub.2-4 alkenyl). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (C.sub.2-3 alkenyl). In some embodiments, an alkenyl group has 2 carbon atoms (C.sub.2 alkenyl). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C.sub.2-4 alkenyl groups include ethenyl (C.sub.2), 1-propenyl (C.sub.3), 2-propenyl (C.sub.3), 1-butenyl (C.sub.4), 2-butenyl (C.sub.4), butadienyl (C.sub.4), and the like. Examples of C.sub.2-6 alkenyl groups include the aforementioned C.sub.2-4 alkenyl groups as well as pentenyl (C.sub.5), pentadienyl (C.sub.5), hexenyl (C.sub.6), and the like. Additional examples of alkenyl include heptenyl (C.sub.7), octenyl (C.sub.8), octatrienyl (C.sub.8), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an unsubstituted alkenyl) or substituted (a substituted alkenyl) with one or more substituents. In certain embodiments, the alkenyl group is an unsubstituted C.sub.2-10 alkenyl. In certain embodiments, the alkenyl group is a substituted C.sub.2-10 alkenyl.
[0047] As used herein, alkynyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon triple bonds (C.sub.2-10 alkynyl). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (C.sub.2-9 alkynyl). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (C.sub.2-8 alkynyl). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (C.sub.2-7 alkynyl). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (C.sub.2-6 alkynyl). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (C.sub.2-5 alkynyl). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (C.sub.2-4 alkynyl). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (C.sub.2-3 alkynyl). In some embodiments, an alkynyl group has 2 carbon atoms (C.sub.2 alkynyl). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C.sub.2-4 alkynyl groups include, without limitation, ethynyl (C.sub.2), 1-propynyl (C.sub.3), 2-propynyl (C.sub.3), 1-butynyl (C.sub.4), 2-butynyl (C.sub.4), and the like. Examples of C.sub.2-6 alkenyl groups include the aforementioned C.sub.2-4 alkynyl groups as well as pentynyl (C.sub.5), hexynyl (C.sub.6), and the like. Additional examples of alkynyl include heptynyl (C.sub.7), octynyl (C.sub.8), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an unsubstituted alkynyl) or substituted (a substituted alkynyl) with one or more substituents. In certain embodiments, the alkynyl group is an unsubstituted C.sub.2-10 alkynyl. In certain embodiments, the alkynyl group is a substituted C.sub.2-10 alkynyl.
[0048] As used herein, carbocyclyl refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (C.sub.3-10 carbocyclyl) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (C.sub.3-8 carbocyclyl). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (C.sub.3-6 carbocyclyl). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (C.sub.3-6 carbocyclyl). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (C.sub.5-10 carbocyclyl). Exemplary C.sub.3-6 carbocyclyl groups include, without limitation, cyclopropyl (C.sub.3), cyclopropenyl (C.sub.3), cyclobutyl (C.sub.4), cyclobutenyl (C.sub.4), cyclopentyl (C.sub.5), cyclopentenyl (C.sub.5), cyclohexyl (C.sub.6), cyclohexenyl (C.sub.6), cyclohexadienyl (C.sub.6), and the like. Exemplary C.sub.3-8 carbocyclyl groups include, without limitation, the aforementioned C.sub.3-6 carbocyclyl groups as well as cycloheptyl (C.sub.7), cycloheptenyl (C.sub.7), cycloheptadienyl (C.sub.7), cycloheptatrienyl (C.sub.7), cyclooctyl (C.sub.5), cyclooctenyl (C.sub.8), bicyclo[2.2.1]heptanyl (C.sub.7), bicyclo[2.2.2]octanyl (C.sub.8), and the like. Exemplary C.sub.3-10 carbocyclyl groups include, without limitation, the aforementioned C.sub.3-8 carbocyclyl groups as well as cyclononyl (C.sub.9), cyclononenyl (C.sub.9), cyclodecyl (C.sub.10), cyclodecenyl (C.sub.10), octahydro-1H-indenyl (C.sub.9), decahydronaphthalenyl (C.sub.10), spiro[4.5]decanyl (C.sub.10), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (monocyclic carbocyclyl) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (bicyclic carbocyclyl) or tricyclic system (tricyclic carbocyclyl)) and can be saturated or can contain one or more carbon-carbon double or triple bonds. Carbocyclyl also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted (an unsubstituted carbocyclyl) or substituted (a substituted carbocyclyl) with one or more substituents. In certain embodiments, the carbocyclyl group is an unsubstituted C.sub.3-10 carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C.sub.3-10 carbocyclyl. In some embodiments, carbocyclyl is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms (C.sub.3-10 cycloalkyl). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (C.sub.3-8 cycloalkyl). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (C.sub.3-6 cycloalkyl). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (C.sub.5-6 cycloalkyl). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (C.sub.5-10 cycloalkyl). Examples of C.sub.5-6 cycloalkyl groups include cyclopentyl (C.sub.5) and cyclohexyl (C.sub.5). Examples of C.sub.3-6 cycloalkyl groups include the aforementioned C.sub.5-6 cycloalkyl groups as well as cyclopropyl (C.sub.3) and cyclobutyl (C.sub.4). Examples of C.sub.3-8 cycloalkyl groups include the aforementioned C.sub.3-6 cycloalkyl groups as well as cycloheptyl (C.sub.7) and cyclooctyl (C.sub.8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an unsubstituted cycloalkyl) or substituted (a substituted cycloalkyl) with one or more substituents. In certain embodiments, the cycloalkyl group is an unsubstituted C.sub.3-10 cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C.sub.3-10 cycloalkyl.
[0049] As used herein, heterocyclyl refers to a radical of a 3- to 14-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (3-14 membered heterocyclyl). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (monocyclic heterocyclyl) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (bicyclic heterocyclyl) or tricyclic system (tricyclic heterocyclyl)), and can be saturated or can contain one or more carbon-carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently unsubstituted (an unsubstituted heterocyclyl) or substituted (a substituted heterocyclyl) with one or more substituents. In certain embodiments, the heterocyclyl group is an unsubstituted 3-14 membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3-14 membered heterocyclyl.
[0050] In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-10 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-8 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-6 membered heterocyclyl). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0051] Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, 1H-benzo[e][1,4]diazepinyl, 1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, 5,6-dihydro-4H-furo[3,2-b]pyrrolyl, 6,7-dihydro-5H-furo[3,2-b]pyranyl, 5,7-dihydro-4H-thieno[2,3-c]pyranyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 4,5,6,7-tetrahydro-1H-pyrrolo-[2,3-b]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, 1,2,3,4-tetrahydro-1,6-naphthyridinyl, and the like.
[0052] As used herein, aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (C.sub.6-14 aryl). In some embodiments, an aryl group has 6 ring carbon atoms (C.sub.6 aryl; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (C.sub.10 aryl; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (C.sub.14 aryl; e.g., anthracyl). Aryl also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently unsubstituted (an unsubstituted aryl) or substituted (a substituted aryl) with one or more substituents. In certain embodiments, the aryl group is an unsubstituted C.sub.6-14 aryl. In certain embodiments, the aryl group is a substituted C.sub.6-14 aryl.
[0053] Aralkyl is a subset of alkyl and refers to an alkyl group, as defined herein, substituted by an aryl group, as defined herein, wherein the point of attachment is on the alkyl moiety.
[0054] As used herein, heteroaryl refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (5-14 membered heteroaryl). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. Heteroaryl includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. Heteroaryl also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl/heteroaryl) ring system. Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-10 membered heteroaryl). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-8 membered heteroaryl). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (5-6 membered heteroaryl). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an unsubstituted heteroaryl) or substituted (a substituted heteroaryl) with one or more substituents. In certain embodiments, the heteroaryl group is an unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is a substituted 5-14 membered heteroaryl.
[0055] Exemplary 5-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing 4 heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing 1 heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include, without limitation, phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl and phenazinyl.
[0056] Heteroaralkyl is a subset of alkyl and refers to an alkyl group, as defined herein, substituted by a heteroaryl group, as defined herein, wherein the point of attachment is on the alkyl moiety.
[0057] As used herein, the term partially unsaturated refers to a ring moiety that includes at least one double or triple bond. The term partially unsaturated is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic groups (e.g., aryl or heteroaryl moieties) as herein defined.
[0058] As used herein, a direct bond refers to the direct attachment of a group via a single bond.
[0059] Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl group). In general, the term substituted, whether preceded by the term optionally or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a substituted group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term substituted is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
[0060] Exemplary carbon atom substituents include, but are not limited to, halogen, CN, NO.sub.2, N.sub.3, SO.sub.2H, SO.sub.3H, OH, OR.sup.aa, ON(R.sup.bb).sub.2, N(R.sup.bb).sub.2, N(R.sup.bb).sub.3 .sup.+X.sup., N(OR.sup.cc)R.sup.bb, SH, SR.sup.aa, SSR.sup.cc, C(O)R.sup.aa, CO.sub.2H, CHO, C(OR.sup.cc).sub.2, CO.sub.2R.sup.aa, OC(O)R.sup.aa, OCO.sub.2R.sup.aa, C(O)N(R.sup.bb).sub.2, OC(O)N(R.sup.bb).sub.2, NR.sup.bbC(O)R.sup.aa, NR.sup.bbCO.sub.2R.sup.aa, NR.sup.bbC(O)N(R.sup.bb).sub.2, C(NR.sup.bb)R.sup.aa, C(NR.sup.bb)OR.sup.aa, OC(NR.sup.bb)R.sup.aa, OC(NR.sup.bb)OR.sup.aa, C(NR.sup.bb)N(R.sup.bb).sub.2, OC(NR.sup.bb)N(R.sup.bb).sub.2, NR.sup.bbC(NR.sup.bb)N(R.sup.bb).sub.2, C(O)NR.sup.bbSO.sub.2R.sup.aa, NR.sup.bbSO.sub.2R.sup.aa, SO.sub.2N(R.sup.bb).sub.2, SO.sub.2R.sup.aa, SO.sub.2OR.sup.aa, OSO.sub.2R.sup.aa, S(O)R.sup.aa, OS(O)R.sup.aa, Si(R.sup.aa).sub.3, OSi(R.sup.aa).sub.3C(S)N(R.sup.bb).sub.2, C(O)SR.sup.aa, C(S)SR.sup.aa, SC(S)SR.sup.aa, SC(O)SR.sup.aa, OC(O)SR.sup.aa, SC(O)OR.sup.aa, SC(O)R.sup.aa, P(O).sub.2R.sup.aa, OP(O).sub.2R.sup.aa, P(O)(R.sup.aa).sub.2, OP(O)(R.sup.aa).sub.2, OP(O)(OR.sup.cc).sub.2, P(O).sub.2N(R.sup.bb).sub.2, OP(O).sub.2N(R.sup.bb).sub.2, P(O)(NR.sup.bb).sub.2, OP(O)(NR.sup.bb).sub.2, NR.sup.bbP(O)(OR.sup.cc).sub.2, NR.sup.bbP(O)(NR.sup.bb).sub.2, P(R.sup.cc).sub.2, P(R.sup.cc).sub.3, OP(R.sup.cc).sub.2, OP(R.sup.cc).sub.3, B(R.sup.aa).sub.2, B(OR.sup.cc).sub.2, BR.sup.aa(OR.sup.cc), C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-14 carbocyclyl, .sub.3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups; or two geminal hydrogens on a carbon atom are replaced with the group O, S, NN(R.sup.bb).sub.2, NNR.sup.bbC(O)R.sup.aa, NNR.sup.bbC(O)OR.sup.aa, NNR.sup.bbS(O).sub.2R.sup.aa, NR.sup.bb, or NOR.sup.cc; each instance of R.sup.aa is, independently, selected from C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl, or two R.sup.aa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups; [0061] each instance of R.sup.bb is, independently, selected from hydrogen, OH, OR.sup.aa, N(R.sup.cc).sub.2, CN, C(O)R.sup.aa, C(O)N(R.sup.cc).sub.2, CO.sub.2R.sup.aa, SO.sub.2R.sup.aa, C(NR.sup.cc)OR.sup.aa, C(NR.sup.cc)N(R.sup.cc).sub.2, SO.sub.2N(R.sup.cc).sub.2, SO.sub.2R.sup.cc, SO.sub.2OR.sup.cc, SOR.sup.aa, C(S)N(R.sup.cc).sub.2, C(O)SR.sup.cc, C(S)SR.sup.cc, P(O).sub.2R.sup.aa, P(O)(R.sup.aa).sub.2, P(O).sub.2N(R.sup.cc).sub.2, P(O)(NR.sup.cc).sub.2, C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl, or two R.sup.bb groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups; each instance of R.sup.cc is, independently, selected from hydrogen, C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl, or two R.sup.cc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups; each instance of R.sup.dd is, independently, selected from halogen, CN, NO.sub.2, N.sub.3, SO.sub.2H, SO.sub.3H, OH, OR.sup.ee, ON(R.sup.ff).sub.2, N(R.sup.ff).sub.2, N(R.sup.ff).sub.3 .sup.+X.sup., N(OR.sup.ee)R.sup.ff, SH, SR.sup.ee, SSR.sup.ee, C(O)R.sup.ee, CO.sub.2H, CO.sub.2R.sup.ee, OC(O) R.sup.ee, OCO.sub.2R.sup.ee, C(O)N(R.sup.ff).sub.2, OC(O)N(R.sup.ff).sub.2, NR.sup.ffC(O)R.sup.ee, NR.sup.ffCO.sub.2R.sup.ee, NR.sup.ffC(O)N(R.sup.ff).sub.2, C(NR.sup.ff)OR.sup.ee, OC(NR.sup.ff)R.sup.ee, OC(NR.sup.ff)OR.sup.ee, C(NR.sup.ff)N(R.sup.ff).sub.2, OC(NR.sup.ff)N(R.sup.ff).sub.2, NR.sup.ffC(NR.sup.ff)N(R.sup.ff).sub.2, NR.sup.ffSO.sub.2R.sup.ee, SO.sub.2N(R.sup.ff).sub.2, SO.sub.2R.sup.ee, SO.sub.2OR.sup.ee, OSO.sub.2R.sup.ee, S(O)R.sup.ee, Si(R.sup.ee).sub.3, OSi(R.sup.ee).sub.3, C(S)N(R.sup.ff).sub.2, C(O)SR.sup.ee, C(S)SR.sup.ee, SC(S)SR.sup.ee, P(O).sub.2R.sup.ee, P(O)(R.sup.ee).sub.2, OP(O)(R.sup.ee).sub.2, OP(O)(OR.sup.ee).sub.2, C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 carbocyclyl, 3-10 membered heterocyclyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg groups, or two geminal R.sup.dd substituents can be joined to form O or S; each instance of R.sup.ee is, independently, selected from C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 carbocyclyl, C.sub.6-10 aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg groups; each instance of R.sup.ff is, independently, selected from hydrogen, C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 carbocyclyl, 3-10 membered heterocyclyl, C.sub.6-10 aryl and 5-10 membered heteroaryl, or two R.sup.ff groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg groups; and each instance of R.sup.gg is, independently, halogen, CN, NO.sub.2, N.sub.3, SO.sub.2H, SO.sub.3H, OH, OC.sub.1-6 alkyl, ON(C.sub.1-6 alkyl).sub.2, N(C.sub.1-6 alkyl).sub.2, N(C.sub.1-6 alkyl).sub.3 .sup.+X.sup., NH(C.sub.1-6 alkyl).sub.2 .sup.+X.sup., NH.sub.2(C.sub.1-6 alkyl).sup.+X.sup., NH.sub.3 .sup.+X.sup., N(OC.sub.1-6 alkyl)(C.sub.1-6 alkyl), N(OH)(C.sub.1-6 alkyl), NH(OH), SH, SC.sub.1-6 alkyl, SS(C.sub.1-6 alkyl), C(O)(C.sub.1-6 alkyl), CO.sub.2H, CO.sub.2(C.sub.1-6 alkyl), OC(O)(C.sub.1-6 alkyl), OCO.sub.2(C.sub.1-6 alkyl), C(O)NH.sub.2, C(O)N(C.sub.1-6 alkyl).sub.2, OC(O)NH(C.sub.1-6 alkyl), NHC(O)(C.sub.1-6 alkyl), N(C.sub.1-6 alkyl)C(O)(C.sub.1-6 alkyl), NHCO.sub.2(C.sub.1-6 alkyl), NHC(O)N(C.sub.1-6 alkyl).sub.2, NHC(O)NH(C.sub.1-6 alkyl), NHC(O)NH.sub.2, C(NH)O(C.sub.1-6 alkyl), OC(NH)(C.sub.1-6 alkyl), OC(NH)OC.sub.1-6 alkyl, C(NH)N(C.sub.1-6 alkyl).sub.2, C(NH)NH(C.sub.1-6 alkyl), C(NH)NH.sub.2, OC(NH)N(C.sub.1-6 alkyl).sub.2, OC(NH)NH(C.sub.1-6 alkyl), OC(NH)NH.sub.2, NHC(NH)N(C.sub.1-6 alkyl).sub.2, NHC(NH)NH.sub.2, NHSO.sub.2(C.sub.1-6 alkyl), SO.sub.2N(C.sub.1-6 alkyl).sub.2, SO.sub.2NH(C.sub.1-6 alkyl), SO.sub.2NH.sub.2, SO.sub.2C.sub.1-6 alkyl, SO.sub.2OC.sub.1-6 alkyl, OSO.sub.2C.sub.1-6 alkyl, SOC.sub.1-6 alkyl, Si(C.sub.1-6 alkyl).sub.3, OSi(C.sub.1-6 alkyl).sub.3C(S)N(C.sub.1-6 alkyl).sub.2, C(S)NH(C.sub.1-6 alkyl), C(S)NH.sub.2, C(O)S(C.sub.1-6 alkyl), C(S)SC.sub.1-6 alkyl, SC(S)SC.sub.1-6 alkyl, P(O).sub.2(C.sub.1-6 alkyl), P(O)(C.sub.1-6 alkyl).sub.2, OP(O)(C.sub.1-6 alkyl).sub.2, OP(O)(OC.sub.1-6 alkyl).sub.2, C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkenyl, C.sub.3-10 carbocyclyl, C.sub.6-10 aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal R.sup.gg substituents can be joined to form O or S; [0062] wherein X.sup. is a counterion.
[0063] As used herein, the term hydroxyl or hydroxy refers to the group OH. The term substituted hydroxyl or substituted hydroxyl, by extension, refers to a hydroxyl group wherein the oxygen atom directly attached to the parent molecule is substituted with a group other than hydrogen, and includes groups selected from OR.sup.aa, ON(R.sup.bb).sub.2, OC(O)SR.sup.aa, OC(O)R.sup.aa, OCO.sub.2R.sup.aa, OC(O)N(R.sup.bb).sub.2, OC(NR.sup.bb)R.sup.aa, OC(NR.sup.bb)OR.sup.aa, OC(NR.sup.bb)N(R.sup.bb).sub.2, OS(O)R.sup.aa, OSO.sub.2R.sup.aa, OSi(R.sup.aa).sub.3, OP(R.sup.cc).sub.2, OP(R.sup.cc).sub.3, OP(O).sub.2R.sup.aa, OP(O)(R.sup.aa).sub.2, OP(O)(OR.sup.cc).sub.2, OP(O).sub.2N(R.sup.bb).sub.2, and OP(O)(NR.sup.bb).sub.2, wherein R.sup.aa, R.sup.bb, and R.sup.cc are as defined herein.
[0064] As used herein, the term thiol or thio refers to the group SH. The term substituted thiol or substituted thio, by extension, refers to a thiol group wherein the sulfur atom directly attached to the parent molecule is substituted with a group other than hydrogen, and includes groups selected from SR.sup.aa, SSR.sup.cc, SC(S)SR.sup.aa, SC(O)SR.sup.aa, SC(O)OR.sup.aa, and SC(O)R.sup.aa, wherein R.sup.aa and R.sup.cc are as defined herein.
[0065] As used herein, the term, amino refers to the group NH.sub.2. The term substituted amino, by extension, refers to a monosubstituted amino or a disubstituted amino, or a trisubstituted amino, as defined herein. In certain embodiments, the substituted amino is a monosubstituted amino or a disubstituted amino group.
[0066] As used herein, the term monosubstituted amino refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with one hydrogen and one group other than hydrogen, and includes groups selected from NH(R.sup.bb), NHC(O)R.sup.aa, NHCO.sub.2R.sup.aa, NHC(O)N(R.sup.bb).sub.2, NHC(NR.sup.bb)N(R.sup.bb).sub.2, NHSO.sub.2R.sup.aa, NHP(O)(OR.sup.cc).sub.2, and NHP(O)(NR.sup.bb).sub.2, wherein R.sup.aa, R.sup.bb and R.sup.cc are as defined herein, and wherein R.sup.bb of the group NH(R.sup.bb) is not hydrogen.
[0067] As used herein, the term disubstituted amino refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with two groups other than hydrogen, and includes groups selected from N(R.sup.bb).sub.2, NR.sup.bbC(O)R.sup.aa, NR.sup.bbCO.sub.2R.sup.aa, NR.sup.bbC(O)N(R.sup.bb).sub.2, NR.sup.bbC(NR.sup.bb)N(R.sup.bb).sub.2, NR.sup.bbSO.sub.2R.sup.aa, NR.sup.bbP(O)(OR.sup.cc).sub.2, and NR.sup.bbP(O)(NR.sup.bb).sub.2, wherein R.sup.aa, R.sup.bb, and R.sup.cc are as defined herein, with the proviso that the nitrogen atom directly attached to the parent molecule is not substituted with hydrogen.
[0068] As used herein, the term trisubstituted amino refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with three groups, and includes groups selected from N(R.sup.bb).sub.3 and N(R.sup.bb).sub.3 .sup.+X.sup., wherein R.sup.bb and X are as defined herein.
[0069] As used herein, the term sulfonyl refers to a group selected from SO.sub.2N(R.sup.bb).sub.2, SO.sub.2R.sup.aa, and SO.sub.2OR.sup.aa, wherein R.sup.aa and R.sup.bb are as defined herein.
[0070] As used herein, the term sulfinyl refers to the group S(O)R.sup.aa, wherein R.sup.aa is as defined herein.
[0071] As used herein, the term carbonyl refers a group wherein the carbon directly attached to the parent molecule is sp.sup.2 hybridized, and is substituted with an oxygen, nitrogen or sulfur atom, e.g., a group selected from ketones (C(O)R.sup.aa), carboxylic acids (CO.sub.2H), aldehydes (CHO), esters (CO.sub.2R.sup.aa, C(O)SR.sup.aa, C(S)SR.sup.aa), amides (C(O)N(R.sup.bb).sub.2, C(O)NR.sup.bbSO.sub.2R.sup.aa, C(S)N(R.sup.bb).sub.2), and imines (C(NR.sup.bb)R.sup.aa, C(NR.sup.bb)OR.sup.aa), C(NR.sup.bb)N(R.sup.bb).sub.2), wherein R.sup.aa and R.sup.bb are as defined herein.
[0072] As used herein, the term silyl refers to the group Si(R.sup.aa).sub.3, wherein R.sup.aa is as defined herein.
[0073] As used herein, a counterion is a negatively charged group associated with a positively charged quarternary amine in order to maintain electronic neutrality. Exemplary counterions include halide ions (e.g., F.sup., Cl.sup., Br.sup., I.sup.), NO.sub.3.sup., ClO.sub.4.sup., OH.sup., H.sub.2PO.sub.4.sup., HSO.sub.4.sup., sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate, ethan-1-sulfonic acid-2-sulfonate, and the like), and carboxylate ions (e.g., acetate, ethanoate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, and the like).
[0074] Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quarternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, OH, OR.sup.aa, N(R.sup.cc).sub.2, CN, C(O)R.sup.aa, C(O)N(R.sup.cc).sub.2, CO.sub.2R.sup.aa, SO.sub.2R.sup.aa, C(NR.sup.bb)R.sup.aa, C(NR.sup.cc) OR.sup.aa, C(NR.sup.cc)N(R.sup.cc).sub.2, SO.sub.2N(R.sup.cc).sub.2, SO.sub.2R.sup.cc, SO.sub.2OR.sup.cc, SOR.sup.aa, C(S)N(R.sup.cc).sub.2, C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl, or two Rec groups attached to an N atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups, and wherein R.sup.aa, R.sup.bb, R.sup.cc and R.sup.dd are as defined above.
[0075] In certain embodiments, the substituent present on the nitrogen atom is an amino protecting group Amino protecting groups include, but are not limited to, OH, OR.sup.aa, N(R.sup.cc).sub.2, C(O)R.sup.aa, C(O)N(R.sup.cc).sub.2, CO.sub.2R.sup.aa, SO.sub.2R.sup.aa, C(NR.sup.cc) R.sup.aa, C(NR.sup.cc)OR.sup.aa, C(NR.sup.cc)N(R.sup.cc).sub.2, SO.sub.2N(R.sup.cc).sub.2, SO.sub.2R.sup.cc, SO.sub.2OR.sup.cc, SOR.sup.aa, C(S)N(R.sup.cc).sub.2, C(O)SR.sup.cc, C(S)SR.sup.cc, C.sub.1-10 alkyl (e.g., aralkyl, heteroaralkyl), C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups, and wherein R.sup.aa, R.sup.bb, R.sup.cc and R.sup.dd are as defined herein Amino protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3.sup.rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
[0076] These and other exemplary substituents are described in more detail in the Detailed Description, the Examples and in the claims. The invention is not intended to be limited in any manner by the above exemplary listing of substituents.
[0077] The compounds useful in the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. As used herein, the term isomers includes any and all geometric isomers and stereoisomers. For example, isomers include cis-and trans-isomers, E- and Z-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. For instance, an isomer/enantiomer may, in some embodiments, be provided substantially free of the corresponding enantiomer, and may also be referred to as optically enriched. Optically enriched, as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound of the present invention is made up of at least about 90% by weight of a particular enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a particular enantiomer. A desired enantiomer may be isolated from a racemic mixture by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) or the formation and crystallization of chiral salts, or the enantiomer may be prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind. 1972).
[0078] As used herein, the term tautomer includes two or more interconvertable compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base. Exemplary tautomerizations include keto-to-enol; amide-to-imide; lactam-to-lactim; enamine-to-imine; and enamine-to-(a different) enamine tautomerizations.
[0079] The term carbohydrate refers to a sugar or polymer of sugars. The terms saccharide, polysaccharide, carbohydrate, and oligosaccharide, may be used interchangeably. Most carbohydrates are aldehydes or ketones with many hydroxyl groups, usually one on each carbon atom of the molecule. Carbohydrates generally have the molecular formula C.sub.nH.sub.2nO.sub.n. A carbohydrate may be a monosaccharide, a disaccharide, trisaccharide, oligosaccharide, or polysaccharide. The most basic carbohydrate is a monosaccharide, such as glucose, sucrose, galactose, mannose, ribose, arabinose, xylose, and fructose. Disaccharides are two joined monosaccharides. Exemplary disaccharides include sucrose, maltose, cellobiose, and lactose. Typically, an oligosaccharide includes between three and six monosaccharide units (e.g., raffinose, stachyose), and polysaccharides include six or more monosaccharide units. Exemplary polysaccharides include starch, glycogen, and cellulose. Carbohydrates may contain modified saccharide units such as 2-deoxyribose wherein a hydroxyl group is removed, 2-fluororibose wherein a hydroxyl group is replace with a fluorine, or N-acetylglucosamine, a nitrogen-containing form of glucose. (e.g., 2-fluororibose, deoxyribose, and hexose). Carbohydrates may exist in many different forms, for example, conformers, cyclic forms, acyclic forms, stereoisomers, tautomers, anomers, and isomers.
[0080] The phrase, pharmaceutically acceptable derivative, as used herein, denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of such compound, or any other adduct or derivative which, upon administration to a patient, is capable of providing (directly or indirectly) a compound as otherwise described herein, or a metabolite or residue thereof. Pharmaceutically acceptable derivatives thus include among others pro-drugs.
[0081] As used herein, the term pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds useful in this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N.sup.+ (C.sub.1-4alkyl).sub.4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Other pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate, and aryl sulfonate.
[0082] Additionally, as used herein, the term pharmaceutically acceptable ester refers to esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moeity advantageously has not more than 6 carbon atoms. Examples of particular esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
[0083] Furthermore, the term pharmaceutically acceptable prodrugs as used herein refers to those prodrugs of the compounds useful in the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the issues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds useful in the invention. The term prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A pro-drug is a derivative of a compound, usually with significantly reduced pharmacological activity, which contains an additional moiety, which is susceptible to removal in vivo yielding the parent molecule as the pharmacologically active species. An example of a pro-drug is an ester or an ether which is cleaved in vivo to yield a compound of interest. Pro-drugs of a variety of compounds, and materials and methods for derivatizing the parent compounds to create the pro-drugs, are known and may be adapted to the present invention. The biological activity of pro-drugs and pro-drugs may also be altered by appending a functionality onto the compound, which may be catalyzed by an enzyme. Also, included are oxidation and reduction reactions, including enzyme-catalyzed oxidation and reduction reactions. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
[0084] As used herein the term inhibit means to reduce the amount of kinase activity to a level or amount that is statistically significantly less than an initial level, which may be a baseline level of kinase activity.
[0085] As used herein, the terms treatment, treat, and treating refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
[0086] As used herein, unless otherwise specified, the terms prevent, preventing and prevention contemplate an action that occurs before a subject begins to suffer from the specified disease or disorder, which inhibits or reduces the severity of the disease or disorder.
[0087] The terms administer, administering, or administration, as used herein refers to implanting, absorbing, ingesting, injecting, or inhaling the compound.
[0088] The term subject refers to any animal. The subject may be at any stage of development. A subject to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs; and/or birds, including commercially relevant birds such as chickens, ducks, geese, and/or turkeys. In some embodiments, the subject is a rodent. In certain embodiments, the subject is an experimental animal such as a mouse, rat, dog, or non-human primate. In certain embodiments, the subject is a transgenic animal.
[0089] The term proliferative disorder as used herein refers to any disease associated with an undesired and/or abnormal proliferation of cells. The cells may be any type of cell found in the subject. The proliferation may be due to any cause (e.g., any genetic mutation, any signal).
[0090] A therapeutically effective amount of a compound comprises administering an amount necessary to achieve a desired result. The exact amount required will vary from subject to subject, depending on the species, age, general condition of the subject, the severity of the disease, the particular anticancer agent, its mode of administration, the desired outcome, and the like. In certain embodiments of the present invention, a therapeutically effective amount of a compound or pharmaceutical composition is that amount effective for inhibiting cell proliferation in a subject or a biological sample (e.g., in cells). In certain embodiments, cell proliferation is inhibited by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 99%. In certain embodiments, the compound inhibits cell proliferation by at least about 25%, at least about 50%, at least about 75%, or at least about 90%. In certain embodiments of the present invention, a therapeutically effective amount refers to an amount of a compound or composition sufficient to inhibit cell proliferation, or refers to an amount of a compound or composition sufficient to reduce the tumor burden in a subject. In certain embodiments, the tumor burden is reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 99%. In certain embodiments, the tumor burden is reduced by at least about 25%, at least about 50%, at least about 75%, or at least about 90%. In certain embodiments of the present invention a therapeutically effective amount of the compound or pharmaceutical composition is that amount effective for reducing or inhibiting the growth of tumor cells and/or killing tumor cells.
[0091] As used herein, a prophylactically effective amount of a compound is an amount sufficient to prevent a disease or disorder, or one or more symptoms associated with the disease or disorder, or prevent its recurrence. A prophylactically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease or disorder. The term prophylactically effective amount can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
[0092] The present invention provides a pharmaceutical composition comprising a combination of (a) a compound of Formula (A) and (b) one or more antineoplastic agents, wherein:
##STR00002##
or a pharmaceutically acceptable salt thereof, [0093] wherein: [0094] each instance of R.sup.1 and R.sup.4 is independently selected from the group consisting of hydrogen, carbonyl, silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; [0095] each instance of R.sup.2 and R.sup.3 is independently selected from the group consisting of hydrogen, halogen, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, carbonyl, silyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R.sup.2 and R.sup.3 are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group; [0096] R.sup.5 is hydrogen and R.sup.6 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; or R.sup.5 and R.sup.6 are joined to form a direct bond; [0097] R.sup.7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; [0098] In certain embodiments, R.sup.1 is hydrogen. In certain embodiments, R.sup.1 is carbonyl, silyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. [0099] In certain embodiments, R.sup.4 is hydrogen. In certain embodiments, R.sup.4 is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. [0100] In certain embodiments, both R.sup.1 and R.sup.4 are hydrogen, e.g., to provide a compound of the Formula (A-1):
##STR00003##
or a pharmaceutically acceptable salt thereof, [0101] wherein R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are as defined herein.
[0102] In certain embodiments, R.sup.2 is hydrogen. In certain embodiments, R.sup.2 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R.sup.2 is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R.sup.2 is optionally substituted heterocyclyl (e.g., optionally substituted tetrahydropyranyl).
[0103] In certain embodiments, R.sup.2 is an optionally substituted tetrahydropyranyl group of the formula (i):
##STR00004## [0104] wherein: [0105] each instance of R.sup.8 is independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, N.sub.2, carbonyl, silyl, sulfonyl, and sulfinyl; and m is 0 or an integer of between 1 and 5, inclusive.
[0106] In certain embodiments, each instance of R.sup.8 is independently selected from optionally substituted alkyl, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, carbonyl, and silyl. In certain embodiments, each instance of R.sup.7 is independently selected from optionally substituted alkyl, OH, substituted hydroxyl, NH.sub.2, and substituted amino. In certain embodiments, each instance of R.sup.8 is independently selected from optionally substituted alkyl, OH, and substituted amino (e.g., disubstituted amino) In certain embodiments, each instance of R.sup.8 is independently selected from CH.sub.3, OH, and N(CH.sub.3).sub.2.
[0107] In certain embodiments, m is an integer of between 1 and 4, inclusive. In certain embodiments, m is an integer of between 1 and 3, inclusive. In certain embodiments, m is an integer of between 1 and 2, inclusive. In certain embodiments, m is 3.
[0108] In certain embodiments, each instance of R.sup.8 is independently selected from CH.sub.3, OH, and N(CH.sub.3).sub.2, and m is an integer of between 1 and 3, inclusive. For example, in this instance, in certain embodiments, R.sup.2 is a substituted tetrahydropyranyl group of the formula (ii):
##STR00005##
[0109] In certain embodiments, the substituted tetrahydropyranyl group of the formula (ii) is of the formula (iii):
##STR00006##
[0110] Alternatively, in certain embodiments, R.sup.2 is an optionally substituted aryl or optionally substituted heteroaryl. In certain embodiments, R.sup.2 is an optionally substituted aryl (e.g., a benzoisochromanequinone).
[0111] In certain embodiments R.sup.2 is substituted benzoisochromanequinone of the formula (iv):
##STR00007## [0112] wherein R.sup.1, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are as defined herein.
[0113] In certain embodiments, the substituted benzoisochromanequinone of formula (iv) is of the formula (v):
##STR00008##
[0114] Alternatively, in certain embodiments, R.sup.2 and R.sup.3 are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group. In certain embodiments, R.sup.2 and R.sup.3 are joined to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl group. In certain embodiments, R.sup.2 and R.sup.3 are joined to form an optionally substituted heterocyclyl group (e.g., an optionally substituted 2-oxabicyclo[2.2.2]octenyl group).
[0115] In certain embodiments, R.sup.2 and R.sup.3 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (vi):
##STR00009## [0116] wherein each instance of R.sup.9 and R.sup.10 is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, carbonyl, silyl, sulfonyl, and sulfinyl.
[0117] In certain embodiments, R.sup.9 is hydrogen. In certain embodiments, R.sup.9 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R.sup.9 is optionally substituted carbocyclyl or optionally substituted heterocyclyl. In certain embodiments, R.sup.9 is optionally substituted heterocyclyl (e.g., optionally substituted tetrahydropyranyl).
[0118] In certain embodiments, R.sup.9 is optionally substituted tetrahydropyranyl group of the formula (vii):
##STR00010## [0119] wherein: [0120] each instance of R.sup.11 is independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, N.sub.2, carbonyl, silyl, sulfonyl, and sulfinyl; and [0121] p is 0 or an integer of between 1 and 5, inclusive.
[0122] In this instance, in certain embodiments, the R.sup.2 and R.sup.3 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (viii):
##STR00011##
[0123] In certain embodiments, each instance of R.sup.11 is independently selected from optionally substituted alkyl, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, carbonyl, and silyl. In certain embodiments, each instance of R.sup.10 is independently selected from optionally substituted alkyl, OH, and substituted hydroxyl. In certain embodiments, each instance of R.sup.11 is independently selected from optionally substituted alkyl and OH. In certain embodiments, each instance of R.sup.11 is independently selected from CH.sub.3 and OH.
[0124] In certain embodiments, p is an integer of between 1 and 4, inclusive. In certain embodiments, p is an integer of between 1 and 3, inclusive. In certain embodiments, p is an integer of between 1 and 2, inclusive. In certain embodiments, p is 2.
[0125] In certain embodiments, each instance of R.sup.11 is independently selected from CH.sub.3 and OH, and p is an integer of between 1 and 2, inclusive. For example, in this instance, in certain embodiments, R.sup.11 is a substituted tetrahydropyranyl group of the formula (ix):
##STR00012##
[0126] In certain embodiments, the substituted tetrahydropyranyl group of the formula (ix) is of the formula (x):
##STR00013##
[0127] In this instance, in certain embodiments, the R.sup.2 and R.sup.3 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (xi):
##STR00014##
[0128] In certain embodiments, R.sup.10 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, carbonyl, silyl, sulfonyl, or sulfinyl.
[0129] However, in certain embodiments, R.sup.10 is hydrogen. In this instance, in certain embodiments, the R.sup.2 and R.sup.3 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (xii):
##STR00015##
[0130] In certain embodiments, both R.sup.9 and R.sup.10 are hydrogen. In this instance, in certain embodiments, the R.sup.2 and R.sup.3 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (xiii):
##STR00016##
[0131] In certain embodiments, R.sup.5 is hydrogen and R.sup.6 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl.
[0132] In certain embodiments, both R.sup.5 and R.sup.6 are hydrogen. However, in certain embodiments, R.sup.5 is hydrogen and R.sup.6 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl.
[0133] Alternatively, in certain embodiments, R.sup.5 and R.sup.6 are joined to form a direct bond, e.g., to provide a dihydrofuran-2-one of the formula (xiv):
##STR00017##
[0134] In certain embodiments, the dihydrofuran-2-one of the formula (xiv) is of the formula (xv):
##STR00018##
[0135] In certain embodiments, the dihydrofuran-2-one of the formula (xiv) is of the formula (xvi):
##STR00019##
[0136] In certain embodiments, R.sup.7 is hydrogen. In certain embodiments, R.sup.7 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl. In certain embodiments, R.sup.7 is optionally substituted alkyl (e.g., CH.sub.3, CH.sub.2CH.sub.3, CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2, and the like). In certain embodiments, R.sup.7 is CH.sub.3.
[0137] In certain embodiments, wherein R.sup.5 and R.sup.6 are joined to form a direct bond, i.e., to provide a dihydrofuran-2-one of the formula (xiv), the compound of Formula (A) is of the Formula (A-2):
##STR00020##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3. In certain embodiments, R.sup.1 and R.sup.4 are hydrogen.
[0138] In certain embodiments, wherein R.sup.5 and R.sup.6 are joined to form a dihydrofuran-2-one of the formula (xv), the compound of Formula (A-2) is of the Formula (A-3):
##STR00021##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3. In certain embodiments, R.sup.1 and R.sup.4 are hydrogen.
[0139] In certain embodiments, wherein R.sup.5 and R.sup.6 are joined to form a dihydrofuran-2-one of the formula (xvi), the compound of Formula (A-2) is of the Formula (A-4):
##STR00022##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3. In certain embodiments, R.sup.1 and R.sup.4 are hydrogen.
[0140] In certain embodiments, wherein R.sup.1 and R.sup.4 are hydrogen, the compound of Formula (A-3) is of the Formula (A-5):
##STR00023##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3.
[0141] In certain embodiments, wherein R.sup.1 and R.sup.4 are hydrogen, the compound of Formula (A-4) is of the Formula (A-6):
##STR00024##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3.
[0142] In certain embodiments, wherein R.sup.2 and R.sup.3 are joined to form a substituted oxabicyclo[2.2.2]octenyl group of the formula (vi), the compound of Formula (A-5) is of the Formula (A-7):
##STR00025##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3.
[0143] Exemplary compounds of Formula (A) or (B) comprise granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin [0144] or pharmaceutically acceptable salts thereof in amorphous form or any crystalline form thereof.
##STR00026## ##STR00027##
[0145] The present invention provides a pharmaceutical composition comprising a combination of (a) a compound of Formula (B) and (b) one or more antineoplastic agents, wherein:
##STR00028##
or pharmaceutically acceptable salts thereof, [0146] wherein: [0147] R.sup.12 is hydrogen, carbonyl, silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; [0148] each instance of R.sup.13 and R.sup.14 is independently selected from the group consisting of hydrogen, halogen, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, carbonyl, silyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R.sup.13 and R.sup.14 are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group; [0149] R.sup.5 is hydrogen and R.sup.6 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; or R.sup.5 and R.sup.6 are joined to form a direct bond; and [0150] R.sup.7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
[0151] In certain embodiments, R.sup.12 is hydrogen. In certain embodiments, R.sup.12 is carbonyl, silyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
[0152] In certain embodiments, R.sup.13 is hydrogen. In certain embodiments, R.sup.13 is halogen, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, carbonyl, silyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl. In certain embodiments, R.sup.13 is OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino. In certain embodiments, R.sup.13 is OH or substituted hydroxyl. In certain embodiments, R.sup.13 is OH.
[0153] In certain embodiments, R.sup.14 is hydrogen. In certain embodiments, R.sup.14 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R.sup.14 is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R.sup.14 is optionally substituted heterocyclyl (e.g., optionally substituted tetrahydropyranyl).
[0154] In certain embodiments, R.sup.14 is an optionally substituted tetrahydropyranyl group of the formula (xvii):
##STR00029## [0155] wherein: [0156] each instance of R.sup.15 is independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, CN, NO.sub.2, carbonyl, silyl, sulfonyl, and sulfinyl; and q is 0 or an integer of between 1 and 5, inclusive.
[0157] In certain embodiments, each instance of R.sup.15 is independently selected from optionally substituted alkyl, OH, substituted hydroxyl, SH, substituted thiol, NH.sub.2, substituted amino, carbonyl, and silyl. In certain embodiments, each instance of R.sup.15 is independently selected from optionally substituted alkyl, OH, substituted hydroxyl, NH.sub.2, and substituted amino. In certain embodiments, each instance of R.sup.15 is independently selected from optionally substituted alkyl, OH, and substituted hydroxyl. In certain embodiments, each instance of R.sup.15 is independently selected from CH.sub.3 and OH.
[0158] In certain embodiments, q is an integer of between 1 and 4, inclusive. In certain embodiments, q is an integer of between 1 and 3, inclusive. In certain embodiments, q is an integer of between 1 and 2, inclusive. In certain embodiments, q is 3.
[0159] In certain embodiments, each instance of R.sup.15 is independently selected from CH.sub.3, OH, and m is an integer of between 1 and 3, inclusive. For example, in this instance, in certain embodiments, R.sup.15 is a substituted tetrahydropyranyl group of the formula (xviii):
##STR00030##
[0160] Alternatively, in certain embodiments, R.sup.13 and R.sup.14 are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group. In certain embodiments, R.sup.13 and R.sup.14 are joined to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl group. In certain embodiments, R.sup.13 and R.sup.14 are joined to form an optionally substituted heterocyclyl group (e.g., an optionally substituted 2-oxabicyclo[2.2.2]octenyl group).
[0161] In certain embodiments, R.sup.13 and R.sup.14 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (xix):
##STR00031##
wherein each instance of R.sup.16 and R.sup.17 is independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, carbonyl, silyl, sulfonyl, and sulfinyl.
[0162] In certain embodiments, R.sup.16 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R.sup.16 is optionally substituted carbocyclyl or optionally substituted heterocyclyl. However, in certain embodiments, R.sup.16 is hydrogen, e.g., and R.sup.13 and R.sup.14 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (xx):
##STR00032##
[0163] In certain embodiments, R.sup.17 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, R.sup.17 is optionally substituted carbocyclyl or optionally substituted heterocyclyl. However, in certain embodiments, R.sup.17 is hydrogen, e.g., and R.sup.13 and R.sup.14 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (xxi):
##STR00033##
[0164] In certain embodiments, both R.sup.16 and R.sup.17 are hydrogen. In this instance, in certain embodiments, the R.sup.13 and R.sup.14 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (xxii):
##STR00034##
[0165] In certain embodiments, R.sup.5 is hydrogen and R.sup.6 is selected from the group consisting of selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl.
[0166] In certain embodiments, both R.sup.5 and R.sup.6 are hydrogen. However, in certain embodiments, R.sup.5 is hydrogen and R.sup.6 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl.
[0167] Alternatively, in certain embodiments, R.sup.5 and R.sup.6 are joined to form a direct bond, e.g., to provide a dihydrofuran-2-one of the formula (xiv):
##STR00035##
[0168] In certain embodiments, the dihydrofuran-2-one of the formula (xiv) is of the formula (xv):
##STR00036##
[0169] In certain embodiments, the dihydrofuran-2-one of the formula (xiv) is of the formula (xvi):
##STR00037##
[0170] In certain embodiments, R.sup.7 is hydrogen. In certain embodiments, R.sup.7 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl. In certain embodiments, R.sup.7 is optionally substituted alkyl (e.g., CH.sub.3, CH.sub.2CH.sub.3, CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2, and the like). In certain embodiments, R.sup.7 is CH.sub.3.
[0171] In certain embodiments, wherein R.sup.12 is hydrogen, the compound of Formula (B) is of the Formula (B-1):
##STR00038##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3.
[0172] In certain embodiments, wherein R.sup.5 and R.sup.6 are joined to form a direct bond, the compound of Formula (B-1) is of the Formula (B-2):
##STR00039##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3.
[0173] In certain embodiments, wherein R.sup.13 and R.sup.14 are joined to form a substituted 2-oxabicyclo[2.2.2]octenyl group of the formula (xix), the compound of Formula (B-1) is of the Formula (B-3):
##STR00040##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3.
[0174] In certain embodiments, wherein R.sup.13 is OH and R.sup.14 is an optionally substituted tetrahydropyranyl group of the formula (xvii), the compound of Formula (B-1) is of the Formula (B-4):
##STR00041##
or a pharmaceutically acceptable salt thereof. In certain embodiments, R.sup.7 is CH.sub.3.
[0175] Exemplary compounds of the Formula (B) include, but are not limited to:
##STR00042##
or pharmaceutically acceptable salts thereof.
[0176] In certain embodiments, the compounds of Formula (A) and (B) have an IC.sub.50 of less than approximately 100 M, e.g., less than approximately 10 M, e.g., less than approximately 1 M, e.g., less than approximately 0.1 M, or e.g., less than approximately 0.01 M.
[0177] The compound of Formula (A) or (B) useful in the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis-and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. As used herein, the term isomers includes any and all geometric isomers and stereoisomers. For example, isomers include cis-and trans-isomers, E-and Z-isomers, R-and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. For instance, an isomer/enantiomer may, in some embodiments, be provided substantially free of the corresponding enantiomer, and may also be referred to as optically enriched. Optically enriched, as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound of the present invention is made up of at least about 90% by weight of a particular enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a particular enantiomer. A desired enantiomer may be isolated from a racemic mixture by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) or the formation and crystallization of chiral salts, or the enantiomer may be prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind. 1972).
[0178] In an embodiment, the compound of Formula (A) or (B) comprises granaticin B or a pharmaceutically acceptable salt thereof in amorphous form or any of its crystalline forms. In an embodiment, the compound of Formula (A) or (B) consists of granaticin B or a pharmaceutically acceptable salt thereof in amorphous or any of its crystalline forms. In an embodiment, the compound of Formula (A) or (B) comprises crystalline Form A of granaticin B. In an embodiment, the crystalline Form A of granaticin B is characterized by X-ray powder diffraction pattern comprising at least 4, 5, 7, 9, 13, or 17 peaks of 9.10.2, 10.00.2, 11.60.2, 16.10.2, 18.30.2, 4.50.2, 15.40.2, 12.60.2, 17.00.2, 13.30.2, 17.50.2, 22.10.2, 23.30.2, 8.70.2, 19.70.2, 20.30.2, and 21.60.2 2-Theta. Various crystalline forms of granaticin B are described in U.S. Pat. No. 10,314,815 which is hereby incorporated by reference in its entirety.
[0179] In some embodiments, a particular crystalline form of granaticin B is substantially free of impurities. As used herein, impurities include, but are not limited to, any extraneous matter such residual solvents, salts, or other forms of granaticin B. In some embodiments, a particular crystalline form of granaticin B is 99% free of impurities. In some embodiments, a particular crystalline form of granaticin B is 97% free of impurities. In some embodiments, a particular crystalline form of granaticin B is 95% free of impurities. In some embodiments, a particular crystalline form of granaticin B is 92% free of impurities. In some embodiments, a particular crystalline form of granaticin B is 90% free of impurities. In certain embodiments, the impurities include extraneous matter, such as a salt forming acid, residual solvents, or any other impurities that may result from the preparation and/or isolation of granaticin B. In some embodiments, a particular crystalline form of granaticin B is substantially free of amorphous form of granaticin B. In some embodiments, a particular crystalline form of granaticin B is substantially free of any other crystalline form of granaticin B. In some embodiments, a particular crystalline form of granaticin B is substantially free of a salt of granaticin B. In some embodiments, a particular crystalline form of granaticin B is substantially free of a solvate of granticin B.
[0180] In some embodiments, Form A is substantially free of impurities. As used herein, impurities include, but are not limited to, any extraneous matter such residual solvents, salts, or other forms of granaticin B. In some embodiments, Form A is 99% free of impurities. In some embodiments, Form A is 97% free of impurities. In some embodiments, Form A is 95% free of impurities. In some embodiments, Form A is 92% free of impurities. In some embodiments, Form A is 90% free of impurities. In certain embodiments, the impurities include extraneous matter, such as a salt forming acid, residual solvents, or any other impurities that may result from the preparation and/or isolation of granaticin B. In some embodiments, Form A is substantially free of amorphous granaticin B. In some embodiments, Form A is substantially free of another crystalline form of granaticin B. In some embodiments, Form A is substantially free of a salt of granaticin B. In some embodiments, Form A is substantially free of a solvate of granaticin B.
[0181] In an embodiment, the compound of Formula (A) or (B) of the present invention is an inhibitor of cell replication cycle. In an embodiment, the compound of Formula (A) or (B) is an inhibitor of cell replication cycle at G1/S phase. In an embodiment, the compound of Formula (A) or (B) is an inhibitor of DNA replication during cell cycle. In an embodiment, the inhibition of cell cycle or the inhibition of DNA replication during the cell cycle by compound of Formula (A) or (B) suppresses abnormal cell proliferation in a subject with a cell proliferation disorder. In an embodiment, the inhibition of cell cycle or the inhibition of DNA replication during the cell cycle by compound of Formula (A) or (B) is useful in suppressing an abnormal cell proliferation of a subject with a proliferation disorder without affecting the proliferation of a normal cell of the subject.
[0182] In an embodiment, the compound of Formula (A) or (B) of the present invention is an inhibitor of a protein kinase. In an embodiment, the compound of Formula (A) or (B) is an inhibitor of cell division cycle 7 (CDC7) kinase. In an embodiment, the compound of Formula (A) or (B) is a non-ATP-competitive inhibitor of CDC7 kinase. In an embodiment, the inhibition of CDC7 kinase involves inhibition of the Dbf4 subunit of CDC7 kinase, wherein the inhibition of CDC7 kinase or the Dbf4 subunit of CDC7 kinase is useful for the treatment of a proliferation disorder.
[0183] In an embodiment, the pharmaceutical composition of the present invention comprises a combination of (a) any embodiment of the compound of Formula (A) or (B) and (b) one or more antineoplastic agents, wherein the one or more antineoplastic agents comprises hydroxyurea, BCL2 inhibitor, hypomethylating agent and/or other chemotherapy drugs. In an embodiment, BCL2 inhibitor comprises Venetoclax, BH3 mimetics or a combination thereof. In an embodiment, the hypomethylation agent comprises azacytidine, decitabine or a combination thereof. In an embodiment, the chemotherapeutic agent comprises cytarabine, daunorbicin, anthracycline or a combination thereof. In an embodiment, the one or more antineoplastic agents of the pharmaceutical composition of the present invention are each in free form, in the form of a pharmaceutically acceptable salt and/or a hydrate thereof.
[0184] Other exemplary chemotherapeutic agents include, but are not limited to, anti-estrogens (e.g. tamoxifen, raloxifene, and megestrol), LHRH agonists (e.g. goscrclin and leuprolide), anti-androgens (e.g. flutamide and bicalutamide), photodynamic therapies (e.g. vertoporfin (BPD-MA), phthalocyanine, photosensitizer Pc4, and demethoxy-hypocrellin A (2BA-2-DMHA)), nitrogen mustards (e.g. cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, estramustine, and melphalan), nitrosoureas (e.g. carmustine (BCNU) and lomustine (CCNU)), alkylsulphonates (e.g. busulfan and treosulfan), triazenes (e.g. dacarbazine, temozolomide), platinum containing compounds (e.g. cisplatin, carboplatin, oxaliplatin), vinca alkaloids (e.g. vincristine, vinblastine, vindesine, and vinorelbine), taxoids (e.g. paclitaxel or a paclitaxel equivalent such as nanoparticle albumin-bound paclitaxel (ABRAXANE), docosahexaenoic acid bound-paclitaxel (DHA-paclitaxel, Taxoprexin), polyglutamate bound-paclitaxel (PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX), the tumor-activated prodrug (TAP) ANG1005 (Angiopep-2 bound to three molecules of paclitaxel), paclitaxel-EC-1 (paclitaxel bound to the erbB2-recognizing peptide EC-1), and glucose-conjugated paclitaxel, e.g., 2-paclitaxel methyl 2-glucopyranosyl succinate; docetaxel, taxol), epipodophyllins (e.g. etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mytomycin C), anti-metabolites, DHFR inhibitors (e.g. methotrexate, dichloromethotrexate, trimetrexate, edatrexate), IMP dehydrogenase inhibitors (e.g. mycophenolic acid, tiazofurin, ribavirin, and EICAR), ribonuclotide reductase inhibitors (e.g. hydroxyurea and deferoxamine), uracil analogs (e.g. 5-fluorouracil (5-FU), floxuridine, doxifluridine, ratitrexed, tegafur-uracil, capecitabine), cytosine analogs (e.g. cytarabine (ara C), cytosine arabinoside, and fludarabine), purine analogs (e.g. mercaptopurine and Thioguanine), Vitamin D3 analogs (e.g. EB 1089, CB 1093, and KH 1060), isoprenylation inhibitors (e.g. lovastatin), dopaminergic neurotoxins (e.g. 1-methyl-4-phenylpyridinium ion), cell cycle inhibitors (e.g. staurosporine), actinomycin (e.g. actinomycin D, dactinomycin), bleomycin (e.g. bleomycin A2, bleomycin B2, peplomycin), anthracycline (e.g. daunorubicin, doxorubicin, pegylated liposomal doxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin, mitoxantrone), MDR inhibitors (e.g. verapamil), Ca.sup.2+ ATPase inhibitors (e.g. thapsigargin), imatinib, thalidomide, lenalidomide, tyrosine kinase inhibitors (e.g., axitinib (AG013736), bosutinib (SKI-606), cediranib (RECENTIN, AZD2171), dasatinib (SPRYCEL, BMS-354825), erlotinib (TARCEVA), gefitinib (IRESSA), imatinib (Gleevec, CGP57148B, STI-571), lapatinib (TYKERB, TYVERB), lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib (TASIGNA), semaxanib (semaxinib, SU5416), sunitinib (SUTENT, SU11248), toceranib (PALLADIA), vandetanib (ZACTIMA, ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab (HERCEPTIN), bevacizumab (AVASTIN), rituximab (RITUXAN), cetuximab (ERBITUX), panitumumab (VECTIBIX), ranibizumab (Lucentis), nilotinib (TASIGNA), sorafenib (NEXAVAR), everolimus (AFINITOR), alemtuzumab (CAMPATH), gemtuzumab ozogamicin (MYLOTARG), temsirolimus (TORISEL), ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120 (VARGATEF), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, and/or XL228), proteasome inhibitors (e.g., bortezomib (VELCADE)), mTOR inhibitors (e.g., rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe) and OSI-027 (OSI)), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbizine, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurosidine, leurosine, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin, aminopterin, and hexamethyl melamine.
[0185] Other chemotherapeutic drugs may comprise Gemtuzumab, ozogamicin, Idarubicin, CPX-351, Enasidenib (IDH2 inibitor), FTL3 inhibitors (Sunitinib, Midostaurin, Lestaurtinib, Crenolanib, Gilteritinib, Sorafenib, Ponatinib, Quizartinib), Ivosidenib (IDH1 inhibitor), Venetoclax (BCL-2 inhibitor) and Glasdegib, rituximab, ofatuzumab (Anti-CD20), inotuzumab ozogamicin (Anti-CD22), blinatumomab (Anti-CD19), and Tisagenlecleucel, tyrosine kinase inhibitor (Imatinib, Dasatinib, Nilotinib, Ponatinib, Bosatinib, Asciminib) with/without chemotherapy (Clofarabine, Nelarabine, Liposomal vincristine, MOpAD, Hyper-CVAD, BFM, etc) or steroid, inotuzumab ozogamicin, blinatumomab, and Tisagenlecleucel.
[0186] In an embodiment, the pharmaceutical composition of the present invention further comprises a pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients include any solvents, diluents or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. In an embodiment, excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition. General considerations in the formulation and/or manufacture of pharmaceutical compositions agents can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
[0187] As shown in Example 5 in connection with FIG. 25 for cell viability experiment on Kasumi-1 cells, azicitydine (Aza) alone had almost no effect, and LBS-007 and Venetoclax (Ven) each alone provided about the same effectiveness on Kasumi-1 cells with cell viability at about 60%. Notably, combination of Aza+Ven as well as LBS-007+Aza provided no additional benefit as compared to LBS-007 or Ven alone, illustrating that double combination therapy do not always result in better results. However, when LBS-007 is combined with Ven, cell viability substantially decreased by almost half to about 35%, demonstrating that the LBS-007 and Ven combination provides synergistic effect. Surprisingly, although Aza alone is shown to have no effect on cell viability, the addition of Aza to LBS-007 and Ven provided nearly 20% improvement to cell viability results.
[0188] As shown in Example 5 in connection with FIG. 26 for cell viability experiment on CESS cells, Ven and Aza alone showed little or no effect on cell viability at the concentration tested whereas LBS-007 demonstrated substantial effect on cell viability at about 50%. Although showing no effect individually, Ven+Aza in combination achieved about 50% cell viability. However, the combinations LBS-007+Aza and LBS-007+Ven doubled effect on cell viability compared to that of the Ven+Aza combination to about 25% cell viability. Most notably, treatment of the CESS cells with the triple combination of LBS-007+Aza+Ven resulted in cell viability of about 7%.
[0189] The Examples demonstrated that therapy with certain combinations of compounds work substantially better than others and that the triple treatment approach especially combining LBS-007, Venetoclax (Ven), and Azacitidine (Aza) in particular proved to be the most effective in inducing cytotoxicity in these acute myeloid leukemia (AML) cell lines. This finding underscores the potential of certain combination treatment as effective therapeutic avenue for AML.
[0190] Therefore, the present invention provides a method of treatment for AML comprising the step of administration of any embodiment of the compound of formula A or B of the present invention disclosed herein in combination with Aza to a subject suffering from AML. The present invention also provides a method of treatment for AML comprising the step of administration of any embodiment of the compound of formula A or B of the present invention disclosed herein in combination with Ven to a subject suffering from AML. In addition, the present invention provides a method of treatment for AML comprising the step of administration of any embodiment of the compound of formula A or B in combination with Aza and Ven to a subject suffering from AML. In an embodiment, the compound of formula A or B comprises graniticin B. In an embodiment, the compound of formula A or B comprises amorphous form of graniticin B. In an embodiment, the compound of formula A or B comprises any crystalline form of graniticin B. In an embodiment, the compound of formula A or B comprises crystalline A form of graniticin B. Various embodiments of compound of formula (A) and (B) are described herein as well as in U.S. Pat. No. 9,180,105 which is hereby incorporated by reference in its entirety.
[0191] The present invention also provides a method of treating a proliferation disorder of a subject comprising the administration of a combination of (a) any embodiment of the compound of Formula (A) or (B) and (b) one or more of any embodiments of the antineoplastic agent of the present invention disclosed herein.
[0192] In an embodiment, the method of treating a proliferation disorder of the present invention comprising the administration of a combination of (a) any embodiment of the compound of Formula (A) or (B) and (b) one or more of any embodiment of the antineoplastic agents of the present invention wherein the (a) any embodiment of the compound of Formula (A) or (B) and (b) the one or more of any embodiment of the antineoplastic agents of the present invention is administered to the subject simultaneously, separately, or sequentially. In an embodiment, the any of the embodiment of the compound of Formula (A) or (B) is administered to a subject before or after the administration of the one or more any embodiment of the antineoplastic agents to the subject. In an embodiment, the any of the embodiment of the compound of Formula (A) or (B) is administered to a subject simultaneously with the administration of the one or more antineoplastic agents to the subject. In an embodiment, the method of treating a proliferation disorder of the present invention comprises the administration of a combination of (a) any embodiment of the compound of Formula (A) or (B) and (b) one of any embodiment of the antineoplastic agents of the present invention. In an embodiment, the method of treating a proliferation disorder of the present invention comprises the administration of a combination of (a) any embodiment of the compound of Formula (A) or (B) and (b) two of any embodiment of the antineoplastic agents of the present invention.
[0193] In an embodiment, the one or more antineoplastic agents comprises azacitidine and venetoclax. In an embodiment, the one or more antineoplastic agents comprises azacitidine. In an embodiment, the one or more antineoplastic agents comprises venetoclax. In an embodiment, the one or more antineoplastic agent comprises fludarabine, arabinofuranosyl cytidine, granulocyte colony-stimulating factor and idarubicin (FLAG-IDA) and wherein administration step comprises the standard FLAG-IDA chemotherapy regimen administered in combination with the compound of Formula (A) or (B). In an embodiment, the one or more antineoplastic agent comprises FLAG-IDA and venetoclax and wherein the administration step comprises the standard FLAG-IDA chemotherapy regimen administered in combination with the compound of Formula (A) or (B). In an embodiment, the one or more antineoplastic agent comprises cytarabine and anthracycline antibiotic and wherein the administration step comprises the standard 7 days of standard-dose cytarabine followed by 3 days of anthracycline antibiotic chemotherapy regimen administered in combination with the compound of Formula (A) or (B). In an embodiment, the one or more antineoplastic agent comprises gilteritinib and azacitidine. In an embodiment, the one or more antineoplastic agent comprises enasidenib and azacitidine. In an embodiment, the one or more antineoplastic agent comprises HiDAC and gileritinib. In an embodiment, the one or more antineoplastic agent comprises oral azacitidine. In an embodiment, the one or more antineoplastic agent comprises ponatinib and standard induction chemotherapy and blinatumomab. In an embodiment, the standard induction chemotherapy comprises any standard induction chemotherapy known in the art. In an embodiment, the standard induction chemotherapy comprises the 7+3 regimen wherein the 7+3 regimen coprises administration of cytarabine continuously for 7 days along with short infusions of an anthracycline on each of the first 3 days. In an embodiment, the one or more antineplastic agent comprises inotuzumab ozogamicin and conventional chemotherapy. In an embodiment, conventional chemotherapy comprises administration of any antineoplastic compound disclosed here or a combination thereof. In an embodiment, the conventional chemotherapy comprises any standard induction chemotherapy known in the art.
[0194] In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agents comprises azacitidine and Venetoclax. In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agents comprises azacitidine. In an embodiment, the one or more antineoplastic agents comprises Venetoclax. In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agent comprises fludarabine, arabinofuranosyl cytidine, granulocyte colony-stimulating factor and idarubicin (FLAG-IDA) and wherein administration step comprises the standard FLAG-IDA chemotherapy regimen administered in combination with the compound of Formula (A) or (B). In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agent comprises FLAG-IDA and venetoclax and wherein administration step comprises the standard FLAG-IDA chemotherapy regimen administered in combination with the compound of Formula (A) or (B). In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agent comprises cytarabine and anthracycline antibiotic and wherein administration step comprises the standard 7 days of standard-dose cytarabine followed by 3 days of anthracycline antibiotic chemotherapy regimen administered in combination with the compound of Formula (A) or (B). In an embodiment, the 7 day standard-dose cytarabine comprises 100 mg/m2/day by continuous IV infusion (Days 1 through 7) or 100 mg/m2 IV every 12 hours (Days 1 through 7). In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agent comprises gilteritinib and azacitidine. In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agent comprises enasidenib and azacitidine. In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agent comprises HiDAC and gileritinib. In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agent comprises oral azacitidine. In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineoplastic agent comprises ponatinib and standard induction chemotherapy and blinatumomab. In an embodiment, the standard induction chemotherapy comprises any standard induction chemotherapy known in the art. In an embodiment, the standard induction chemotherapy comprises the 7+3 regimen wherein the 7+3 regimen coprises administration of cytarabine continuously for 7 days along with short infusions of an anthracycline on each of the first 3 days. In an embodiment, the compound of Formula (A) or (B) comprises granticin B and the one or more antineplastic agent comprises inotuzumab ozogamicin and conventional chemotherapy. In an embodiment, convention chemotherapy comprises administration of any antineoplastic compound disclosed here or a combination thereof. In an embodiment, the conventional chemotherapy comprises any standard induction chemotherapy known in the art
[0195] In an embodiment, the proliferation disorder comprises cancer, myeloproliferative disorders, benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, fibrotic disorders, pulmonary fibrosis, arthritis, rheumatoid arthritis, glomerulonephritis, and post-surgical stenosis, restenosis, disorders of proliferation of blood vessels, disorders of proliferation of mesangial cells, metabolic disorders, allergies, asthmas, thromboses, diseases of the nervous system, retinopathy, diabetes, and muscular degeneration.
[0196] In an embodiment, the proliferative disorder comprises cancer, wherein the cancer is originated from at least a part of a subject body comprising bone, brain, connective tissue, endocrine glands, adrenal cortex, endometrium, germ cells, head and neck, larynx and hypopharynx, mesothelioma, muscle, rectum, renal, small intestine, soft tissue, testis, ureter, vagina, and vulva. In an embodiment, the proliferative disorder comprises cancer, wherein the cancer comprises bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, esophagus cancer, gallbladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, papillary thyroid carcinoma, genitourinary malignancies, retinoblastoma, Wilms tumor, myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, renal cell carcinoma, Ewing's sarcoma, desmoplastic small round cell tumors, mesothelioma, skin cancer comprising squamous cell carcinoma, hematologic cancers comprising leukemia, acute lymphocytic leukemia (ALL), acute lymphoblastic leukemia, lymphoma, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, mantle cell lymphoma (MCL), hairy cell lymphoma, Burkitt's lymphoma, chronic lymphocytic leukemia (CLL), multiple myeloma, chronic myeloid leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome, promyelocytic leukemia, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma, glioma, schwannomas, melanoma, cutaneous melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pegmentosum, keratoxanthoma, thyroid follicular cancer, Kaposi's sarcoma, cancers of unknown primary site, solid tumors, hematologic cancers, and AIDS-related malignancies.
[0197] In certain embodiments, the cancer is a multi-drug resistant (MDR) cancer such as AML or TKI (tyrosine kinase inhibitor)-resistant Ph+ ALL (Philadelphia chromosome positive acute lymphoblastic leukemia). In certain embodiments, the cancer is relapsed and/or refractory cancer. Relapsed cancer refers to a cancer which has returned after a patient has enjoyed a remission. Refractory cancer refers to a cancer which does not respond to other therapies or therapeutic agents. In certain embodiments, the cancer is resistant to (i.e., does not respond to) therapies or chemotherapeutic agents. In certain embodiments, the hematologic cancer is resistant to therapies or chemotherapeutic agents.
[0198] In certain embodiments, the cancer is leukemia, lymphoma, melanoma, cancer of the breast, stomach, ovaries, colon, rectum, lung, brain, larynx, lymphatic system, thyroid, oesophagus, liver, uterus, testis, bladder, prostate, bones or pancreas. In certain embodiments, the cancer is leukemia, cancer of the breast, the colon or the lung.
[0199] In certain embodiments, the cancer is a hematologic cancer. In certain embodiments, the compound inhibits the growth of hematologic cancers. In certain embodiments, the compound inhibits the growth of hematologic cancers with IC50s in the nanomolar range. In certain embodiments, the hematologic cancer is a hematopoietic cancer of lymphoid lineage. In certain embodiments, the hematologic cancer is a relapsed and/or refractory hematopoietic cancer of lymphoid lineage. In certain embodiments, the cancer is refractory to multiple cycles of cancer therapy (e.g., including allogenic bone marrow transplantation). In certain embodiments, the hematologic cancer is relapsed and/or refractory ALL, CLL, AML, or CML.
[0200] In certain embodiments, the cancer is ovarian cancer. In certain embodiments, the ovarian cancer is ovarian carcinoma.
[0201] In certain embodiments, the cancer is lung cancer. In certain embodiments, the lung cancer is non-small cell lung cancer. In certain embodiments, the lung cancer is small cell lung cancer. In certain embodiments, the lung cancer is lung adenocarcinoma.
[0202] In certain embodiments, the cancer is prostate cancer.
[0203] In certain embodiments, the cancer is renal cell carcinoma.
[0204] In certain embodiments, the cancer is cervical cancer. In certain embodiments, the cervical cancer is cervical adenocarcinoma. In certain embodiments, the cervical cancer is positive for human papillomavirus (HPV) infection.
[0205] In certain embodiments, the cancer is glioblastoma.
[0206] In certain embodiments, the cancer is retinoblastoma.
[0207] In certain embodiments, the cancer is rhabdomyosarcoma.
[0208] In certain embodiments, the cancer is a desmoplastic small round cell tumor.
[0209] In certain embodiments, the cancer is breast cancer. In certain embodiments, the breast cancer is breast ductal carcinoma. In certain embodiments, the breast cancer is breast adenocarcinoma. In certain embodiments, the breast cancer is metastatic breast adenocarcinoma. In certain embodiments, the breast cancer is HER2 negative. In certain embodiments, the breast cancer is HER2 positive. In certain embodiments, the breast cancer is NEU receptor negative.
[0210] In certain embodiments, the cancer is mesothelioma.
[0211] In certain embodiments, the cancer is melanoma.
[0212] In certain embodiments, the cancer is thyroid carcinoma.
[0213] In certain embodiments, the cancer is Ewing's sarcoma.
[0214] In certain embodiments, the cancer is a solid tumor. In certain embodiments, the compound inhibits the growth of solid tumors. In certain embodiments, the compound inhibits the growth of solid tumors with IC50s in the nanomolar range.
[0215] In certain embodiments, the cancer comprises a genetic mutation.
[0216] In certain embodiments, the cancer comprises a RAS mutation. In certain embodiments, the cancer comprises wild-type RAS.
[0217] In certain embodiments, cancer comprises an EGFR mutation. In certain embodiments, the EGFR mutation is an L858R EGFR mutation. In certain embodiments, the EGFR mutation is an DelE746 EGFR mutation. In certain embodiments, the EGFR mutation is an DelE746-A750 EGFR mutation. In certain embodiments, the EGFR mutation is an DelE746-E749 EGFR mutation. In certain embodiments, the EGFR mutation is an T790M EGFR mutation. In certain embodiments, the EGFR mutation is an T790M/L858R EGFR mutation. In certain embodiments, the cancer comprises wild-type EGFR.
[0218] In certain embodiments, the cancer comprises a KRAS mutation. In certain embodiments, the cancer comprises a G13C KRAS mutation. In certain embodiments, the cancer comprises a G12C KRAS mutation. In certain embodiments, the cancer comprises a G12C KRAS mutation. In certain embodiments, the cancer comprises a Q61H KRAS mutation. In certain embodiments, the cancer comprises wild-type KRAS.
[0219] In certain embodiments, the cancer comprises a p53 mutation. In certain embodiments, the p53 mutation is a R273H p53 mutation. In certain embodiments, the p53 mutation is a G262V p53 mutation. In certain embodiments, the p53 mutation is a G16L p53 mutation. In certain embodiments, the p53 mutation is a C176F p53 mutation. In certain embodiments, the p53 mutation is a M246I p53 mutation. In certain embodiments, the cancer comprises wild-type p53.
[0220] In certain embodiments, the cancer comprises a BRAF mutation. In certain embodiments, the BRAF mutation is a BRAF V600E mutation.
[0221] In certain embodiments, the cancer comprises a EVI1 mutation.
[0222] In certain embodiments, the cancer comprises a Flt-3 mutation.
[0223] In certain embodiments, the cancer comprises a WT-1 mutation.
[0224] In certain embodiments, the cancer comprises a cyclin D mutation.
[0225] In certain embodiments, the cancer comprises a PTEN mutation.
[0226] In certain embodiments, the cancer comprises a ABL kinase mutation.
[0227] In certain embodiments, the mutation comprises a chromosomal abnormality. In
[0228] certain embodiments, the chromosomal abnormality is a chromosome deletion or inversion.
[0229] In certain embodiments, the cancer comprises a chromosome 17p deletion. In certain embodiments, the cancer comprises an inversion of chromosome 16. In certain embodiments, the cancer comprises a trisomy of chromosome 8. In certain embodiments, the cancer comprises a monosomy of chromosome 7. In certain embodiments, the cancer comprises a chromosome 11q23 abnormality. In certain embodiments, the cancer comprises a Philadelphia chromosome positive abnormality.
[0230] In certain embodiments, the cancer comprises a fusion transcript. In certain embodiments, the fusion transcript is a reciprocal ASPL-TFE3 fusion transcript.
[0231] In an embodiment, the method of treating a proliferation disorder of the present invention can be administered in combination with additional cancer therapies that improves their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body. In an embodiment, the additional cancer therapy comprises surgical treatments, radiation therapy, and therapeutic agents. In an embodiment, the additional cancer therapy is administered to a subject before or after the method of treating a proliferation disorder to the subject of the present invention. In an embodiment, the additional cancer therapy is administered to a subject simultaneously with the method of treating a proliferation disorder to the subject of the present invention.
[0232] In certain embodiments, a therapeutically effective amount of any embodiment of the compound of Formula (A) or (B) or any embodiment of the antineoplastic agent for administration one or more times a day to a 70 kg adult human may comprise about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, about 0.001 mg to about 100 mg, from about 0.01 mg to about 50 mg, from about 0.1 mg to about 40 mg, from about 0.5 mg to about 30 mg, from about 0.01 mg to about 10 mg, from about 0.1 mg to about 10 mg, and from about 1 mg to about 25 mg, per kilogram, of a compound. It will be appreciated that dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult. The desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
[0233] In an embodiment, the ratio by weight of the compound of Formula (A) or (B) of the present invention to any embodiment of the antineoplastic agent in a combination of the present invention is about 500:1 to about 1:500 such as about 500:1, about 400:1, about 300:1, about 200:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 1.5:1, about 1:1, about 1:0.9, about1: 0.8, about 1:0.7, about 1:0.6, about 1:0.5, about 1:0.4, about 1:0.3, about 1:0.2 or about 1:0.1, about 1:1.5, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:200, about 1:300, about 1:400 or about 1:500 including any numbers and ranges falling within these values.
EXAMPLES
[0234] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
Example 1. Inhibition of Primary Patient Samples
[0235] Table 1 highlights a series of primary patient leukemia samples-both acute and chronic and treatment nave and refractory and the effect of granaticin A, granaticin B, derivative 1, and derivative 2 to inhibit cellular proliferation. The IC50 data reveals that granaticin B is approximately one log more active than granaticin A against all the samples tested and inhibits cellular proliferation in the low nanomolar range. The two starred samples represent serial samples taken from the same patients after they received 2-3 cycles of additional high dose salvage chemotherapy and indicate that although refractory to salvage chemotherapy, the Cdc7 pathway remains a potentially efficacious target as the sensitivity to these compounds remains unchanged. Importantly, each patient sample was resistant to the prior therapy received using this assay.
TABLE-US-00001 TABLE 1 Inhibition of patient leukemia samples IC.sub.50 (microM) Leukemia sample Granaticin A Deriv. 1 Deriv. 2 Granaticin B AML, de novo 0.72 0.62 2.01 0.18 AML, primary 0.75 0.62 1.55 0.11 refractory 1 AML, primary 0.63 0.47 1.44 0.10 refractory 1* AML, primary 0.77 0.84 1.45 0.14 refractory AML, relapsed 1.20 0.70 2.23 0.10 AML, relapsed 0.21 0.23 0.35 0.05 AML, relapsed s/p 1.88 1.86 8.10 0.62 HSCT AMMoL 0.99 0.79 5.88 0.49 ALL, Ph+ 0.56 0.47 2.57 0.19 Biphenotypic acute 0.30 0.69 0.90 0.04 leukemia 1 Biphenotypic acute 0.54 0.76 1.02 0.10 leukemia 1* CML, untreated 0.26 0.33 1.24 0.08 CLL, untreated, 0.46 0.36 1.21 0.31 chromosome 17p del. PhALL3.1 0.14 0.12 0.47 0.03 *Indicates a second sample from the same patient following high-dose chemotherapy
TABLE-US-00002 TABLE 2 IC.sub.50 (microM) Cell Line Description Granaticin A Granaticin B ALL3 Hematopoietic-Human 0.14 0.03 Acute Lymphoblastic leukemia; Philadelphia chromosome positive HL60 Hematopoietic-Human 0.14 0.09 Acute Promyelocytic leukemia HL60 MX1 Hematopoietic-Human 0.17 0.08 Acute Promyelocytic leukemia; MDR variant of HL60 selected with mitoxantrone-clone 1 HL60 MX2 Hematopoietic-Human 0.11 0.07 Acute Promyelocytic leukemia; MDR variant of HL60 selected with mitoxantrone-clone 2 HL60 RV Hematopoietic-Human 0.09 0.07 Acute Promyelocytic leukemia: MDR variant of HL60 selected with vincristine JEKO Hematopoietic-Human 0.04 0.02 Mantle Cell Lymphoma JURKAT E61 Hematopoietic-Human 0.05 0.02 Acute Lymphoblastic T- cell leukemia K562 Hematopoietic-Human 0.12 0.08 Chronic Myelogenous leukemia transformed to acute erythroleukemia KASUMI4 Hematopoietic-Human 0.30 0.18 Chronic Myelogenous leukemia transformed to acute myeloid leukemia- overexpression of EVI1 MEG01 Hematopoietic-Human 0.17 0.08 Chronic Myelogenous leukemia transformed to acute Megakaryoblastic leukemia MOLT3 Hematopoietic-Human 0.03 0.01 Acute Lympholastic T-cell Leukemia NCEB1 Hematopoietic-Human 0.33 0.26 Mantle Cell Lymphoma 132 Primary-Patient sample of 0.13 0.01 Chronic Lymphocytic Leukemia ALBU Primary-Patient sample of 0.43 0.03 essential thrombocythemia transformed to refractory acute myelogenous leukemia DOGO Primary-Patient sample of 0.15 0.07 Chronic Lymphocytic Leukemia with trisomy of chromosome 12 and unmutated Ig heavy chain locus GLHU Primary-Patient sample of 0.26 0.08 Chronic Myelogenous leukemia JABR Primary-Patient sample of 0.21 0.05 relpased/refractory acute myelogenous leukemia with normal cytogenetics and Flt-3 ITD JAKL Primary-Patient sample of 0.05 0.01 Chronic Lymphocytic Leukemia with trisomy of chromosome 12 and unmutated Ig heavy chain locus JAMC Primary-Patient sample of 0.06 0.04 acute myelogenous leukemia with inversion of chromosome 16 JAQU Primary-Patient sample of 0.05 0.01 relapsed/refractory pre-B cell acute lymphoblastic leukemia JOBL Primary-Patient sample of 0.56 0.19 relapsed/refractory acute myelogenous leukemia JOHO Primary-Patient sample of 0.88 0.17 primary refractory acute myelogenous leukemia with inv3 and monosomy 7 (refractory to allogeneic BMT) JOQU Primary-Patient sample of 0.77 0.14 relapsed/refractory acute myelogenous leukemia with trisomy of chromosome #8 and Flt-3 ITD JUCO Primary-Patient sample of 0.08 0.01 pre-B cell acute lymphoblastic leukemia with t(4; 11) involving the MLL gene MAWI Primary-Patient sample of 0.72 0.18 relpased/refractory acute myelogenous leukemia with normal cytogenetics MAWI B Primary-Patient sample of 0.42 0.16 secondary chronic myelogenous leukemia MIHA Primary-Patient sample of 0.30 0.04 relapsed/refractory acute biphenotypic leukemia (patient was refractory to allogeneic bone marrow transplant) PAPR Primary-Patient sample of 0.99 0.49 relapsed acute myelomonocytic leukemia RADO Primary-Patient sample of 0.06 0.03 primary refractory acute myelogenous leukemia with multiple chromosomal abnormalities (5, 7) RORI Primary-Patient sample of 1.20 0.10 relapsed/refractory acute myelogenous leukemia with trisomy of chromosome #8 SOPA Primary-Patient sample of 0.10 0.09 secondary acute myelogenous leukemia with chromsome 11q23 abnormality STGL Primary-Patient sample of 1.88 0.62 refractory acute myelogenous leukemia with multiple chromosomal abnormalities(refractory to allogeneic BMT) A2780 Solid-Human ovarian 0.12 0.02 carcinoma A549 Solid-Human lung 0.28 0.09 adenocarcinoma; G12S KRAS mutation BE(2)C Solid-human 0.07 0.04 neuroblastoma; p53 mutant CWR22 Solid-human prostate 0.09 0.04 carcinoma FUUR1 Solid-human renal cell 0.48 0.34 carcinoma with the reciprocal ASPL-TFE3 fusion transcript H11-18 Solid-Human lung 0.42 0.06 adenocarcinoma; L858R EGFR mutation H1650 Solid- Human lung 0.29 0.06 adenocarcinoma; DelE746- A750 EGFR mutation; wild-type RAS; PTEN null H1734 Solid-Human lung 0.24 0.04 adenocarcinoma; G13C KRAS mutation H1975 Solid-Human lung 0.12 0.03 adenocarcinoma; T790M/L858R EGFR mutation; R273H p53 mutation; PTEN null; wild-type KRAS H2030 Solid-human lung 0.49 0.22 adenocarcinoma; wild-type EGFR; G12C KRAS mutation; G262V P53 mutation; PTEN null H2122 Solid-human lung 1.19 0.21 adenocarcinoma; G12C KRAS mutation; Q16L and C176F P53 mutations H23 Solid-Human lung 0.12 0.05 adenocarcinoma; G12c KRAS mutation; M246I P53 mutation H2444 Solid-human lung 0.31 0.03 adenocarcinoma; G12V KRAS mutation H3255 Solid-Human lung 0.21 0.07 adenocarcinoma; L858R EGFR mutation; wild-type KRAS; wild-type P53 H358 Solid-Human lung 0.21 0.05 adenocarcinoma; G13C KRAS mutation H460 Solid-human lung 0.39 0.08 adenocarcinoma; Q61H KRAS mutation H820 Solid-human lung 0.09 0.05 adenocarcinoma; DelE746- E749 and T790M EGFR mutations HCC4011 Solid-Human lung 0.14 0.05 adenocarcinoma; L858R EGFR mutation; wild-type KRAS HCC827 Solid-human lung 0.28 0.12 adenocarcinoma; DelE746- A750 EGFR mutation HELA N10 Solid-human cervical 1.27 0.97 adenocarcinoma (positive for human papillomavirus infection) HPLD1 Solid-Immortalized human 0.18 0.04 bronchiolar epithelial cell with SV-40 Large T antigen HTB15 Solid-Human 0.65 0.46 Glioblastoma (U-118MG), classified as Grade IV JNDSRCT1 Solid-Human desmoplastic 0.07 0.05 small round cell tumor cell line MCF-10A Solid-human normal 0.26 0.24 mammary epithelium MCF-7 Solid-human invasive 0.17 0.13 breast ductal carcinoma, estrogen and progesterone receptor positive MDA-MB-231 Solid-human metastatic 0.47 0.29 breast adenocarcinoma; estrogen, progesterone, and HER2/NEU receptor negative MESO47 Solid-human 0.61 0.38 mesothelioma; WT-1 overexpression OVCAR3 Solid-human ovarian 0.21 0.11 adenocarcinoma PC9 Solid-Human lung 0.30 0.07 adenocarcinoma; DelE746- A750 EGFR mutation RB355 Solid-Human 0.09 0.04 retinoblastoma RH30 Solid-Human 0.13 0.08 rhabdomyosarcoma; P53 mutation SKMEL28 Solid-Human melanoma 0.54 0.34 SKOV3 Solid-Human 0.12 0.04 adenocarcinoma from the ovary derived from ascites; hypodiploid SW1736 Solid-Human anaplastic 0.16 0.02 thyroid carcinoma with BRAF V600E mutation TC71 Solid-Human Ewing's 0.15 0.09 sarcoma Y79 Solid-Human 0.06 0.05 retinoblastoma
Example 3. Stability Studies Using Granaticin A
[0236] Standard liver microsome stability tests were performed with mouse and human microsomes with granaticin A and revealed that this drug is cleared quickly by the liver. The stability of granaticin A was determined in mouse and human liver microsomes. In mouse liver microsomes, recovery at 30 minutes was 3.68%. In mouse liver microsomes, recovery at 60 minutes was 3.84%. In human liver microsomes, recovery at 30 minutes was 23.89%. In human liver microsomes, recovery at 60 minutes was 12.01%.
Example 4. Preliminary Screening of Granaticin B
[0237] Standard solubility studies were conducted with granaticin B. In aqueous solution, 4.0 mg/ml of granaticin B is soluble. In alcohol, >188 mg/ml of granaticin B is soluble. In methanol, >252 mg/ml of granaticin B is soluble.
[0238] Different formulations of granaticin B were also tested and PK data measured (see Table 3).
TABLE-US-00003 TABLE 3 Preliminary Mouse PK Screening Granaticin B, Mouse PK AUC.sub.inf Half-life C.sub.max CL screening 5 mg/kg (hr g/mL) (t.sub.2/1.sup.) (g/mL) (mL/hr/kg) A: 1.25% of Ethanol & 3532.5 6.9 2834.7 1415.4 Tween-20 B: 0.6% GDO-12 477981.5 3445.5 2537.2 10.5 C: 5% GDP-12 2689.9 6.6 2449.9 1858.8 D: DMSO 2724.5 2.1 2210.9 1835.2
Example 5 In Vitro Inhibition of Kasumi-1 and CESS cells
Methods and Materials
Cell Culture
[0239] Kasumi-1 and CESS cells were cultured in RPMI medium containing 30% and 10% fetal bovine serum (FBS), respectively. For each experimental condition, cells were seeded in 96-well plate at a density of 110{circumflex over ()}5 cells/ml for each well.
Drug Treatments
[0240] The three drugs, LBS-007 (007) is granaticin B, Venetoclax (Ven), and Azacitidine (Aza), were administered at fixed concentrations to the cells.
Control Group: Cells Received no Drug Treatment
[0241] Single treatment Group: Cells were treated with single drug. (007, Ven or Aza) [0242] Double Treatment Group: Cells were treated with a combination of two drugs. (007+Ven, 007+Aza, Ven+Aza) [0243] Triple Treatment Group: Cells were simultaneously treated with all three drugs. (007+Ven+Aza)
Dose and Duration
[0244] Single treatment and combinations of LBS-007 (007), Venetoclax (Ven) and Azacytidine (Aza) at 40 nM, 20 nM and 500 nM respectively were treated for a duration of 72 hours.
Cell Viability Assessment
[0245] Cell viability was assessed using the CCK-8 assay. Following the completion of the 72-hour drug treatments, CCK-8 reagent was added to each well at 10% of the total volume, and the cells were incubated for an additional 1.5 hours. The absorbance of 450 nm was measured using a SpectraMax iD3 microplate reader (Molecular Devices).
Statistical Analysis
[0246] Statistical analyses were conducted to assess the significance of observed differences among the experimental groups. Initially, a one-way ANOVA was employed to determine whether there were overall differences among the control, double treatment, and triple treatment groups. Subsequently, Student's two-tailed t-test was used to analyze data sets. Results with * p<0.05, **p<0.01, and ***p<0.001 were considered significant when compared to Control (Ctrl). Results with #p<0.05, ##p<0.01, and ###p<0.001 were considered significant when compared as indicated. All experimental data are reported as the mean and the error bars represent the experimental standard error (standard deviation, SD).
[0247] The experiment focused on two types of acute myeloid leukemia (AML) cell lines, Kasumi-1 and CESS, representing different subtypes within the AML spectrum. The Kasumi-1 cells are myeloblast cells that was isolated from the peripheral blood of an acute myeloblastic leukemia Asian male patient. CESS cells are lymphoblast cells isolated from the blood of a White male with myelomonocytic leukemia. The results are shown in
[0248] As shown in
[0249] As shown in
[0250] The results of our investigation demonstrated that the triple treatment approach, combining LBS-007, Venetoclax (Ven), and Azacitidine (Aza), proved to be the most effective in inducing cytotoxicity in these AML cell lines. This finding underscores the potential of the triple treatment strategy as a promising combination therapeutic avenue for AML.